<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Adv</journal-id><journal-id journal-id-type="iso-abbrev">Sci Adv</journal-id><journal-id journal-id-type="publisher-id">sciadv</journal-id><journal-id journal-id-type="hwp">advances</journal-id><journal-title-group><journal-title>Science Advances</journal-title></journal-title-group><issn pub-type="epub">2375-2548</issn><publisher><publisher-name>American Association for the Advancement of Science</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39018397</article-id><article-id pub-id-type="pmc">PMC466946</article-id><article-id pub-id-type="publisher-id">adk4920</article-id><article-id pub-id-type="doi">10.1126/sciadv.adk4920</article-id><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biomedicine and Life Sciences</subject></subj-group><subj-group subj-group-type="legacy-article-type"><subject>SciAdv r-articles</subject></subj-group><subj-group subj-group-type="field"><subject>Biophysics</subject><subject>Virology</subject></subj-group><subj-group subj-group-type="overline"><subject>Virology</subject></subj-group></article-categories><title-group><article-title>Single-molecule imaging reveals allosteric stimulation of SARS-CoV-2 spike receptor binding domain by host sialic acid</article-title><alt-title alt-title-type="short">Sialic acid activates SARS-CoV-2 S</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>D&#x000ed;az-Salinas</surname><given-names>Marco A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2827-6263</contrib-id><name><surname>Jain</surname><given-names>Aastha</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0077-4770</contrib-id><name><surname>Durham</surname><given-names>Natasha D.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7634-4633</contrib-id><name><surname>Munro</surname><given-names>James B.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><xref rid="award1404220" ref-type="award"/><xref rid="award1404221" ref-type="award"/><xref rid="award1404219" ref-type="award"/></contrib><aff id="aff1"><label><sup>1</sup></label>Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</aff><aff id="aff2"><label><sup>2</sup></label>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Email: <email xlink:href="james.munro@umassmed.edu">james.munro@umassmed.edu</email> (J.B.M); <email xlink:href="marco.diaz@umassmed.edu">marco.diaz@umassmed.edu</email> (M.A.D.-S.)</corresp></author-notes><pub-date pub-type="collection"><day>19</day><month>7</month><year>2024</year></pub-date><pub-date publication-format="electronic" date-type="pub"><day>17</day><month>7</month><year>2024</year></pub-date><volume>10</volume><issue>29</issue><elocation-id>eadk4920</elocation-id><history>
<date date-type="received"><day>25</day><month>8</month><year>2023</year></date>
<date date-type="accepted"><day>13</day><month>6</month><year>2024</year></date>
</history><permissions><copyright-statement>Copyright &#x000a9; 2024 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense" start_date="2024-07-17">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-NonCommercial license</ext-link>, which permits use, distribution, and reproduction in any medium, so long as the resultant use is <bold>not</bold> for commercial advantage and provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="sciadv.adk4920.pdf"/><abstract><p>Conformational dynamics of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (S) mediate exposure of the binding site for the cellular receptor, angiotensin-converting enzyme 2 (ACE2). The N-terminal domain (NTD) of S binds terminal sialic acid (SA) moieties on the cell surface, but the functional role of this interaction in virus entry is unknown. Here, we report that NTD-SA interaction enhances both S-mediated virus attachment and ACE2 binding. Through single-molecule F&#x000f6;rster resonance energy transfer imaging of individual S trimers, we demonstrate that SA binding to the NTD allosterically shifts the S conformational equilibrium, favoring enhanced exposure of the ACE2-binding site. Antibodies that target the NTD block SA binding, which contributes to their mechanism of neutralization. These findings inform on mechanisms of S activation at the cell surface.</p></abstract><abstract abstract-type="teaser"><p>Host sialic acids promote the open conformation of SARS-CoV-2 S receptor binding domain to facilitate ACE2 binding.</p></abstract><funding-group><award-group id="award1404220"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap>
</funding-source><award-id>R01GM143773</award-id></award-group><award-group id="award1404221"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap>
</funding-source><award-id>R01AI174645</award-id></award-group><award-group id="award1404219"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>UMass Chan Medical School Pandemic Relief Fund</institution></institution-wrap>
</funding-source><award-id>N/A</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>Copyeditor</meta-name><meta-value>Vivian Hernandez</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction" disp-level="1"><title>INTRODUCTION</title><p>The etiologic agent of the COVID-19 pandemic is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>). SARS-CoV-2 binds the cellular receptor, angiotensin-converting enzyme 2 (ACE2), through its envelope glycoprotein spike (S), which subsequently enables entry into the host cell by promoting fusion of viral and cellular membranes (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>&#x02013;<xref rid="R10" ref-type="bibr"><italic toggle="yes">10</italic></xref>). The viral spike is a trimer of heterodimers with each protomer consisting of S1 and S2 subunits. The S1 subunit contains the receptor binding domain (RBD), which includes the ACE2 receptor binding motif (RBM). The S2 subunit forms the stalk of the spike, which undergoes a large-scale refolding during membrane fusion (<xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>&#x02013;<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>). The importance of other spike domains during virus entry into cells, such as the N-terminal domain (NTD) of S1, is less well established. Neutralizing monoclonal antibodies (mAb) that target the NTD, such as mAb 4A8, suggest a biological relevance for the NTD in infection (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>&#x02013;<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>). Moreover, the NTD may play a critical role in allosterically regulating proteolysis of S during entry into cells (<xref rid="R18" ref-type="bibr"><italic toggle="yes">18</italic></xref>&#x02013;<xref rid="R20" ref-type="bibr"><italic toggle="yes">20</italic></xref>).</p><p>Structures of soluble trimeric S ectodomains identified two prefusion conformations in which the RBD adopts either a &#x0201c;down&#x0201d; or an &#x0201c;up&#x0201d; position (<xref rid="R6" ref-type="bibr"><italic toggle="yes">6</italic></xref>, <xref rid="R8" ref-type="bibr"><italic toggle="yes">8</italic></xref>, <xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>&#x02013;<xref rid="R25" ref-type="bibr"><italic toggle="yes">25</italic></xref>). The RBM is occluded in the RBD-down conformation, suggesting that transition to the RBD-up position is required for binding ACE2. Structures of S bound to ACE2 showing the RBD in the up conformation support this hypothesis (<xref rid="R10" ref-type="bibr"><italic toggle="yes">10</italic></xref>). Furthermore, real-time analysis of the conformational dynamics of S through single-molecule F&#x000f6;rster resonance energy transfer (smFRET) imaging corroborated the structural data (<xref rid="R26" ref-type="bibr"><italic toggle="yes">26</italic></xref>&#x02013;<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). Analysis of the kinetics of conformational transitions indicated that ACE2 does not induce movement of the RBD but, rather, captures the RBD-up conformation (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). This observation suggests that promoting the RBD-up conformation might increase ACE2 binding.</p><p>In addition to interaction with ACE2, some reports have demonstrated that the RBD binds heparan sulfate oligosaccharides, ABH blood group antigens, and monosialylated gangliosides (<xref rid="R29" ref-type="bibr"><italic toggle="yes">29</italic></xref>&#x02013;<xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>). In contrast, other studies have shown low or undetectable binding between the RBD and carbohydrates (<xref rid="R36" ref-type="bibr"><italic toggle="yes">36</italic></xref>&#x02013;<xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>). Therefore, the existence of RBD-carbohydrate interactions remains controversial. Computational approaches also suggested the existence of sialoside-binding motifs in the NTD that can bind to 5-acetylneuraminic acid (Neu5Ac) present in compounds like ganglioside GM1 and &#x003b1;2,3- and &#x003b1;2,6-linked sialyl <italic toggle="yes">N</italic>-acetyllactosamines (<xref rid="R39" ref-type="bibr"><italic toggle="yes">39</italic></xref>&#x02013;<xref rid="R42" ref-type="bibr"><italic toggle="yes">42</italic></xref>). Experimental studies have since provided direct evidence in support of a sialoside-binding site in the NTD (<xref rid="R36" ref-type="bibr"><italic toggle="yes">36</italic></xref>, <xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>&#x02013;<xref rid="R45" ref-type="bibr"><italic toggle="yes">45</italic></xref>). These studies presented the possibility that SARS-CoV-2 may exploit glycans on the cell surface to aid in attachment. Support for this hypothesis came from a study in which depletion of sialic acid (SA) levels on ACE2-expressing cells through genetic, pharmacological, or enzymatic approaches decreased RBD binding and entry of SARS-CoV-2 virions (<xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>). Similarly, atomic force microscopy demonstrated that synthetic multimeric SA glycoclusters could decrease S-pseudotyped virus binding to model cell lines (<xref rid="R46" ref-type="bibr"><italic toggle="yes">46</italic></xref>). Moreover, inhibition of SARS-CoV-2 infection in a nonhuman cell line by &#x003b1;2,6- sialoside compounds, but not by the &#x003b1;2,3- analog, was reported. Consistently, binding of SARS-CoV-2 spike S1 subunit to the same cells was competitively inhibited by &#x003b1;2,6-linked sialosides (<xref rid="R47" ref-type="bibr"><italic toggle="yes">47</italic></xref>). Despite these findings, which in general support a role for S interaction with sialylated glycans during SARS-CoV-2 attachment to host cells, the interplay and relative contributions of SA and ACE2 binding has not been elucidated.</p><p>In this study, we explore the role of the NTD during early interactions with the host cell. Our data further support a role for the NTD in mediating SARS-CoV-2 attachment to cells through engagement with SA on the cell surface, which is blocked by NTD-targeting mAb 4A8. In addition, we demonstrate that SA binding to the NTD stimulates subsequent interaction of S with ACE2. The mechanistic basis for this phenomenon is provided by smFRET imaging of trimeric S ectodomains, which indicates that the SA-NTD interaction shifts the equilibrium of RBD toward the up position, thus promoting exposure of the ACE2-binding site (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). Overall, our findings support a critical role for the NTD in enabling initial attachment of SARS-CoV-2 to the cell surface and promoting subsequent engagement with ACE2.</p></sec><sec sec-type="results" disp-level="1"><title>RESULTS</title><sec disp-level="2"><title>Soluble SA compounds enhance S-mediated SARS-CoV-2 entry</title><p>We first sought to verify the role of SA during infection of cells with SARS-CoV-2 S&#x02013;pseudotyped virus. We formed pseudotyped virions with SARS-CoV-2 S and the HIV-1 core containing a luciferase reporter gene. The pseudovirions were then used to infect 293T cells that stably express both human ACE2 and TMPRSS2 (293T-ACE2.TMPRSS2; fig. S1A) (<xref rid="R48" ref-type="bibr"><italic toggle="yes">48</italic></xref>, <xref rid="R49" ref-type="bibr"><italic toggle="yes">49</italic></xref>). We incubated the pseudovirions with different concentrations (0 to 1.5 mM) of either dextrose [a non-carboxylated monosaccharide with inert binding properties to SARS-CoV-2 S (<xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>)], Neu5Ac, or &#x003b1;2,3- or &#x003b1;2,6-linked sialylated oligosaccharides [sialosides; LS-tetrasaccharides a (LSTa) or LSTc, respectively] (<xref rid="F1" ref-type="fig">Fig. 1A</xref>). Preincubation with dextrose had no effect on pseudovirus infectivity. Preincubation with the SA-containing compounds resulted in statistically significant increases in infectivity at concentrations up to 150 &#x003bc;M (<xref rid="F1" ref-type="fig">Fig. 1A</xref> and fig. S1B). Concentrations greater than 150 &#x003bc;M inhibited infection, with complete inhibition seen at 1.5 mM LSTa and LSTc (<xref rid="F1" ref-type="fig">Fig. 1A</xref>). We also evaluated the infectivity of pseudovirions incubated with different concentrations (0.14 to 1.4 &#x003bc;M) of a monomeric, soluble human ACE2 (shACE2, fig. S1C). As expected, incubation of pseudovirions with 1.4 &#x003bc;M shACE2 resulted in more than twofold reduction in infectivity (fig. S1C), irrespective of the absence or presence of 150 &#x003bc;M SA (fig. S1D) (<xref rid="R50" ref-type="bibr"><italic toggle="yes">50</italic></xref>, <xref rid="R51" ref-type="bibr"><italic toggle="yes">51</italic></xref>). To distinguish the relative importance of SA on the cell surface from exogeneous SA-containing compounds during SARS-CoV-2 S&#x02013;mediated entry, we repeated the infectivity experiments with 293T-ACE2.TMPRSS2 cells pretreated with neuraminidase (NA) to remove cell-surface SA. Treatment of cells with NA resulted in 18 &#x000b1; 5% decrease in pseudovirus infectivity compared with untreated cells (fig. S1, E and B). Preincubation of pseudovirions with 150 &#x003bc;M Neu5Ac, LSTa, or LSTc increased infectivity nearly to the level seen in cells not treated with NA, whereas dextrose again had no effect (<xref rid="F1" ref-type="fig">Fig. 1B</xref>). Here again, preincubation with shACE2 reduced infectivity of NA-treated cells (fig. S1F). These data demonstrate that the interaction of cellular SA with SARS-CoV-2 S enhances infectivity, in agreement with previous reports (<xref rid="R46" ref-type="bibr"><italic toggle="yes">46</italic></xref>, <xref rid="R47" ref-type="bibr"><italic toggle="yes">47</italic></xref>). Furthermore, the dependence on ACE2 is maintained irrespective of the presence of SA.</p><fig position="float" id="F1" fig-type="image" specific-use="distribute"><label>Fig. 1.</label><caption><title>SA enhances SARS-CoV-2 S&#x02013;mediated infectivity and virus entry.</title><p>(<bold>A</bold>) Quantification of pseudovirion infectivity in 293T-ACE2.TMPRSS2 cells using a luciferase reporter. Particles were incubated with the indicated glycan concentrations before inoculation of cells. (<bold>B</bold>) Pseudovirion infectivity in 293T-ACE2.TMPRSS2 cells pretreated with NA to remove cell-surface terminal SAs. Viral particles were preincubated with 150 &#x003bc;M of the indicated glycan or 1.4 &#x003bc;M shACE2 before inoculation of cells. (<bold>C</bold>) Quantification of pseudovirion entry into 293T-ACE2.TMPRSS2 cells using a BlaM reporter (<xref rid="R52" ref-type="bibr"><italic toggle="yes">52</italic></xref>). Particles were incubated with 150 &#x003bc;M of the indicated glycan or with 125 nM of the indicated mAb. As a negative control for mAb-mediated inhibition of virus entry, irrelevant (Irr) mAb was included. (<bold>D</bold>) Pseudovirion entry in 293T-ACE2.TMPRSS2 cells pretreated with NA. Pseudovirions were preincubated as in (C). In all cases, infectivity or virus entry are presented as a percentage of that seen in the case of mock preincubation without glycan, shACE2, or mAb. Individual values, the arithmetic means, and SDs of three independent experiments performed in triplicate are shown. Statistical significance was evaluated through one-way analysis of variance (ANOVA) followed by Dunnett&#x02019;s multiple comparisons test. <italic toggle="yes">P</italic> values are shown, and those &#x0003c;0.05 were considered statistically significant. ns, not significant.</p></caption><graphic xlink:href="sciadv.adk4920-f1" position="float"/></fig><p>We next focused on the importance of SA during virus entry. We used a virus entry assay using pseudovirions containing &#x003b2;-lactamase (BlaM) fused to the HIV-1 Vpr protein (fig. S1G) (<xref rid="R52" ref-type="bibr"><italic toggle="yes">52</italic></xref>). Consistent with the infectivity measurements, pseudovirions preincubated with 150 &#x003bc;M Neu5Ac, LSTa, or LSTc resulted in 28 &#x000b1; 4%, 22 &#x000b1; 5%, and 32 &#x000b1; 9% increase in virus entry into 293T-ACE2.TMPRSS2 cells, respectively, while dextrose had no effect (<xref rid="F1" ref-type="fig">Fig. 1C</xref>). Preincubation of pseudovirions with 125 nM of mAb 1A9, which inhibits membrane fusion driven by SARS-CoV S (<xref rid="R53" ref-type="bibr"><italic toggle="yes">53</italic></xref>), decreased virus entry by 34 &#x000b1; 4% (<xref rid="F1" ref-type="fig">Fig. 1C</xref>), confirming that the observed virus entry was mediated by S. Treatment of cells with NA resulted in approximately 30% reduction of virus entry (fig. S1H), which was recovered through incubation of pseudovirions with Neu5Ac, LSTa, or LSTc (<xref rid="F1" ref-type="fig">Fig. 1D</xref>). Together, these data indicate that SA can increase infectivity by enhancing S-mediated virus entry into 293T-ACE2.TMPRSS2 cells.</p></sec><sec disp-level="2"><title>SARS-CoV-2 S mediates virus-cell attachment through interaction with SA</title><p>The apparent role of SA in promoting S-mediated entry into cells led us to hypothesize that SA might be facilitating attachment of virions to the cell surface. We produced pseudovirions with SARS-CoV-2 S and the HIV-1 core containing green fluorescent protein (GFP) (fig. S2A). To determine whether S can mediate attachment to cells lacking ACE2, we incubated GFP-containing pseudovirions with 293T cells on ice. We removed unbound virus and quantified GFP fluorescence, which indicated viral attachment to cells (fig. S2B). To test the role of SA in the observed virus attachment, we preincubated the pseudovirus with different concentrations (0 to 1.5 mM) of dextrose, Neu5Ac, LSTa, or LSTc before incubation with the 293T cells (<xref rid="F2" ref-type="fig">Fig. 2A</xref>). Treatment with SA-containing compounds resulted in concentration-dependent inhibition of virus-cell binding, with approximately 50% reduction at 150 &#x003bc;M to nearly complete inhibition at higher concentrations (up to 1.5 mM, <xref rid="F2" ref-type="fig">Fig. 2A</xref>). Specifically, the treatment with 150 &#x003bc;M Neu5Ac reduced virus attachment by 53 &#x000b1; 5%, while the same concentration of LSTa and LSTc reduced virus attachment by 56 &#x000b1; 15% and 62 &#x000b1; 11%, respectively (<xref rid="F2" ref-type="fig">Fig. 2A</xref> and fig. S2C). In contrast, neither preincubation with dextrose nor shACE2 had any effect on virus attachment to 293T cells (fig. S2, C and D). Last, pretreatment of cells with NA reduced virus attachment by 60% (<xref rid="F2" ref-type="fig">Fig. 2B</xref> and fig. S2, E and F). These data indicate that SA can enable S-mediated virus attachment to the cell surface in the absence of ACE2. Furthermore, the similarity in the results involving LSTa and LSTc indicate that the glycosidic linkage of the SA is not a determinant of the interaction.</p><fig position="float" id="F2" fig-type="image" specific-use="distribute"><label>Fig. 2.</label><caption><title>SA modulates S-mediated attachment of virions to cells.</title><p>(<bold>A</bold>) Quantification of GFP fluorescence resulting from pseudovirion attachment to 293T cells lacking ACE2 expression. Particles were incubated with the indicated glycan concentrations before adsorption on cells. (<bold>B</bold>) 293T cells treated with NA to remove cell-surface terminal SAs were inoculated with viral particles preincubated with 150 &#x003bc;M of the indicated glycan or 1.4 &#x003bc;M shACE2. (<bold>C</bold>) Quantification of pseudovirion attachment to 293T-ACE2 cells following incubation with the indicated glycan concentrations. (<bold>D</bold>) The same data acquired following treatment of 293T-ACE2 cells with NA. Data are expressed as the percentage of virus attachment with respect to the binding observed with mock-treated virus. Individual values, the arithmetic means, and SDs of three independent experiments performed in duplicate are shown. Statistical significance was evaluated through one-way ANOVA followed by Dunnett&#x02019;s multiple comparisons test. <italic toggle="yes">P</italic> values are shown, and those &#x0003c;0.05 were considered statistically significant. ns, not significant.</p></caption><graphic xlink:href="sciadv.adk4920-f2" position="float"/></fig><p>We next sought to determine the role of SA during virus attachment to cells expressing ACE2. Approximately five-times more virus attached to 293T cells stably expressing ACE2 (293T-ACE2) as compared to 293T cells lacking ACE2 (fig. S2, B and G). As before, we preincubated fluorescent pseudovirions with different concentrations of dextrose, Neu5Ac, LSTa, or LSTc before incubation with 293T-ACE2 cells (<xref rid="F2" ref-type="fig">Fig. 2C</xref>). Incubation with dextrose had no effect on pseudovirion binding. Preincubation of pseudovirions with 150 &#x003bc;M Neu5Ac, LSTa, or LSTc, resulted in 25 &#x000b1; 6%, 19 &#x000b1; 5%, and 31 &#x000b1; 10% increase in virus attachment to 293T-ACE2 cells, respectively, while lower concentrations had no effect (<xref rid="F2" ref-type="fig">Fig. 2C</xref> and fig. S2H). Incubation with higher concentrations resulted in reductions of cell binding, with complete abrogation seen at 1.5 mM LSTa or LSTc (<xref rid="F2" ref-type="fig">Fig. 2C</xref>). When cells were pretreated with NA to remove SA from the cell surface, virus attachment to 293T-ACE2 cells decreased by 15 &#x000b1; 7% (fig. S2I). This result is consistent with the reduction of infectivity in 293T-ACE2.TMPRSS2 cells pretreated with NA (fig. S1E). Other reports using different cell lines have indicated variable impact of NA treatment, ranging from no effect to similar reductions in virus binding and infectivity (<xref rid="R47" ref-type="bibr"><italic toggle="yes">47</italic></xref>, <xref rid="R54" ref-type="bibr"><italic toggle="yes">54</italic></xref>, <xref rid="R55" ref-type="bibr"><italic toggle="yes">55</italic></xref>). Preincubation of pseudovirions with Neu5Ac, LSTa, or LSTc restored attachment to levels seen in the absence of NA treatment (<xref rid="F2" ref-type="fig">Fig. 2D</xref>). Incubation of pseudovirions with any glycan tested in addition to shACE2 resulted in an ~60 to 70% decrease in binding to 293T-ACE2, whether or not cells were treated with NA (fig. S2, J and K). These results emphasize that S binding to ACE2 is the primary mediator of virus attachment. These results also show that the presence of SA-containing compounds can enhance attachment to ACE2-expressing cells.</p></sec><sec disp-level="2"><title>Soluble SA compounds enhance shACE2 binding by SARS-CoV-2 spikes</title><p>The results above are consistent with SA and ACE2 promoting attachment of SARS-CoV-2 to the cell surface through distinct mechanisms. Alternatively, interaction of S with SA and ACE2 might work in concert to facilitate efficient attachment. To differentiate between these two possibilities, we next asked whether interaction of S with SA affects subsequent binding of S to ACE2. We used a previously validated fluorescence correlation spectroscopy (FCS) assay to evaluate shACE2 binding to SARS-CoV-2 S ectodomain trimers (S&#x00394;TM) in solution (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). FCS provides a means of quantifying molecular interactions by measuring the timescale of diffusion of a fluorescent species before and after interaction with a binding partner. We first incubated S&#x00394;TM with varying concentrations of SA-containing glycans or dextrose, followed by introduction of a fixed concentration of shACE2, which had been fluorescently labeled with Cy5 (<xref rid="F3" ref-type="fig">Fig. 3A</xref>). We then quantified the S&#x00394;TM-ACE2 interaction using FCS as described in Materials and Methods. Incubation of S&#x00394;TM trimers with Neu5Ac, LSTa, or LSTc resulted in increased shACE2 binding (<xref rid="F3" ref-type="fig">Fig. 3, B to D</xref>). The extent of shACE2 binding increased with the concentration of SA-containing glycans and reached an approximately twofold increase at the highest concentration of 300 &#x003bc;M. Treatment of S&#x00394;TM spikes with dextrose did not affect shACE2 binding. No significant difference in the extent of enhancement of shACE2 binding was seen across the three SA-containing glycans considered here. These results suggest that interaction of the SARS-CoV-2 S with SA enhances subsequent binding of S to ACE2, with no dependence on the nature of the glycosidic linkage of SA.</p><fig position="float" id="F3" fig-type="image" specific-use="distribute"><label>Fig. 3.</label><caption><title>SA enhances shACE2 binding to SARS-CoV-2.</title><p>(<bold>A</bold>) Scheme of the FCS assay used to evaluate Cy5-labeled shACE2 (tan) binding to S&#x00394;TM (cyan) (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). (<bold>B</bold> to <bold>E</bold>) Cy5-labeled shACE2 was incubated in the absence or presence of S&#x00394;TM spikes preincubated with the indicated concentration of dextrose (B), Neu5Ac (C), LSTa (D), or LSTc (E). FCS data were acquired and fit as described in Materials and Methods. Data are expressed as fold change of shACE2 binding to glycan-treated S&#x00394;TM with respect to the binding observed with untreated S&#x00394;TM. Violin plots show the distribution of individual binding values (blue dots), the median (gray circles), and the mean shACE2 binding (horizontal lines) from at least two independent experiments, each consisting of at least 20 10-s acquisitions. Vertical lines extend to the 25th and 75th quantiles. Statistical significance was evaluated through one-way ANOVA. <italic toggle="yes">P</italic> values are shown, and those &#x0003c;0.05 were considered statistically significant.</p></caption><graphic xlink:href="sciadv.adk4920-f3" position="float"/></fig></sec><sec disp-level="2"><title>SARS-CoV-2 S binds to SA on the cell surface through the NTD</title><p>Evidence from in silico, biochemical, and structural approaches suggests that the NTD domain of SARS-CoV-2 S binds SA-containing compounds like gangliosides (<xref rid="R36" ref-type="bibr"><italic toggle="yes">36</italic></xref>, <xref rid="R39" ref-type="bibr"><italic toggle="yes">39</italic></xref>&#x02013;<xref rid="R41" ref-type="bibr"><italic toggle="yes">41</italic></xref>, <xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>, <xref rid="R44" ref-type="bibr"><italic toggle="yes">44</italic></xref>). We therefore investigated whether the NTD could be involved in the attachment of virions to the cell surface. We evaluated the binding to either 293T or 293T-ACE2 cells of GFP-labeled pseudovirions incubated with the neutralizing mAb 4A8, which targets the NTD of S without interfering with its binding to ACE2 (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>). Targeting S with 4A8 decreased attachment of pseudovirions to 293T cells by 61 &#x000b1; 5% (<xref rid="F4" ref-type="fig">Fig. 4A</xref>, orange bars). Incubation of pseudovirions with both 4A8 and shACE2 together resulted in a similar observation, indicating that the RBD does not have a substantial role in binding to 293T cells lacking ACE2 expression (<xref rid="F4" ref-type="fig">Fig. 4A</xref>, cyan bars). In contrast, incubation of pseudovirions with 4A8 had no significant effect on binding to 293T-ACE2 cells (<xref rid="F4" ref-type="fig">Fig. 4B</xref>, green bars), consistent with previous observations (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>). As expected, coincubation of pseudovirions with 4A8 and shACE2 decreased attachment to 293T-ACE2 cells by approximately 70% (<xref rid="F4" ref-type="fig">Fig. 4B</xref>, purple bars). These results suggest that S can attach to the surface of cells lacking ACE2 by way of the NTD and that 4A8 blocks the interaction between the NTD and the cell surface. When viewed together with previously published work (<xref rid="R36" ref-type="bibr"><italic toggle="yes">36</italic></xref>, <xref rid="R39" ref-type="bibr"><italic toggle="yes">39</italic></xref>&#x02013;<xref rid="R41" ref-type="bibr"><italic toggle="yes">41</italic></xref>, <xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>, <xref rid="R44" ref-type="bibr"><italic toggle="yes">44</italic></xref>), these data support the hypothesis that the NTD facilitates attachment to the cell surface through SA binding.</p><fig position="float" id="F4" fig-type="image" specific-use="distribute"><label>Fig. 4.</label><caption><title>SARS-CoV-2 S NTD mediates virus binding to cells.</title><p>(<bold>A</bold>) Quantification of the binding of fluorescent SARS-CoV-2 S pseudovirions preincubated with 625 nM of either 4A8 or an irrelevant (Irr) antibody, 1.4 &#x003bc;M of shACE2, or with the indicated combination, to 293T cells. (<bold>B</bold>) Quantification of binding of fluorescent pseudovirions pretreated as in (A) to 293T-ACE2 cells. Data are expressed as the percentage of virus bound to cells compared to the binding of untreated virus. Individual values, the arithmetic means, and SDs of three independent experiments performed in duplicate are shown. Statistical significance was evaluated through nonparametric Kruskal-Wallis test, and <italic toggle="yes">P</italic> values were obtained from comparisons against the mock-incubated virus. <italic toggle="yes">P</italic> values &#x0003c;0.05 were considered statistically significant.</p></caption><graphic xlink:href="sciadv.adk4920-f4" position="float"/></fig><p>To test this hypothesis, we evaluated the role of the S NTD in binding SA using surface plasmon resonance (SPR). We covalently attached the &#x003b1;2,6-linked sialoside glysyl-6&#x02032;-sialyllactose (GSL) to sensor chips as indicated in Materials and Methods. First, we validated the GSL-sensor chips by evaluating the binding of the lectin <italic toggle="yes">Sambucus nigra</italic> agglutinin (SNA, fig. S3A), which specifically binds &#x003b1;2,6-linked sialosides (<xref rid="R56" ref-type="bibr"><italic toggle="yes">56</italic></xref>). The equilibrium dissociation constant (<italic toggle="yes">K</italic><sub>d</sub>) calculated from binding SNA to our GSL-sensor chip was 544.7 &#x000b1; 6.79 nM, in agreement with a previously reported value obtained using similar methodology (<xref rid="R56" ref-type="bibr"><italic toggle="yes">56</italic></xref>). We next determined the binding properties of S&#x00394;TM trimers to the GSL-sensor chip. This resulted in calculation of an average <italic toggle="yes">K</italic><sub>d</sub> of 1.36 &#x000b1; 0.399 nM (<xref rid="F5" ref-type="fig">Fig. 5A</xref> and fig. S3B). This value is similar to reported <italic toggle="yes">K</italic><sub>d</sub>s for S&#x00394;TM trimer binding to heparin sulfate, mAb 2G12, which targets an epitope consisting of glycans in the S2 domain, as well as other lectins binding to SA (<xref rid="R29" ref-type="bibr"><italic toggle="yes">29</italic></xref>, <xref rid="R31" ref-type="bibr"><italic toggle="yes">31</italic></xref>, <xref rid="R33" ref-type="bibr"><italic toggle="yes">33</italic></xref>, <xref rid="R56" ref-type="bibr"><italic toggle="yes">56</italic></xref>, <xref rid="R57" ref-type="bibr"><italic toggle="yes">57</italic></xref>). We then evaluated the impact of mAb 4A8 on S&#x00394;TM binding to the GSL-sensor chips (<xref rid="F5" ref-type="fig">Fig. 5B</xref> and fig. S3C). Preincubation of S&#x00394;TM with mAb 4A8 resulted in a 68 &#x000b1; 6% reduction of S&#x00394;TM binding to the GSL-sensor chip (<xref rid="F5" ref-type="fig">Fig. 5C</xref>). This result indicates that SARS-CoV-2 S NTD binds sialosides through a mechanism that is inhibited by mAb 4A8.</p><fig position="float" id="F5" fig-type="image" specific-use="distribute"><label>Fig. 5.</label><caption><title>The NTD-directed mAb 4A8 blocks binding of S&#x00394;TM trimers to GSL.</title><p>(<bold>A</bold>) Representative sensorgram indicating binding of S&#x00394;TM trimers to the surface of sensor chips coated with the sialoside GSL. The arithmetic mean of the kinetic parameters of the S&#x00394;TM binding to GSL-sensor chips was calculated from two independent experiments as described in Materials and Methods. (<bold>B</bold>) Representative SPR sensorgram showing the binding of S&#x00394;TM trimers previously incubated with 600 nM of either mAb 4A8 or an irrelevant (Irr) antibody to the surface of sensor chips coated with GSL. Mock incubation was performed in the absence of mAb. (<bold>C</bold>) Quantification of the maximum binding of S&#x00394;TM to the GSL-sensor chips like those shown in (B). Data are expressed as the percentage of bound S&#x00394;TM with respect to the binding observed with mock-incubated S&#x00394;TM. Individual values, the arithmetic means, and SDs from four independent experiments are shown. Statistical significance was evaluated through one-way ANOVA test, and <italic toggle="yes">P</italic> values from comparisons against the binding of mock-treated S&#x00394;TM to GSL-sensor chips are shown.</p></caption><graphic xlink:href="sciadv.adk4920-f5" position="float"/></fig><p>To further confirm this observation, we sought to determine whether SA interaction with the NTD could interfere with 4A8 binding. To this end, we developed an alternative SPR assay in which S&#x00394;TM was preincubated with sialoside compounds followed by evaluation of S&#x00394;TM binding to 4A8 immobilized on the sensor chip. In the absence of sialoside, S&#x00394;TM bound the 4A8-sensor chip with an average <italic toggle="yes">K</italic><sub>d</sub> = 0.42 &#x000b1; 0.07 nM (<xref rid="F6" ref-type="fig">Fig. 6A</xref> and fig. S3D), in approximate agreement with the previously reported value (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>). Incubation of S&#x00394;TM trimers with 300 &#x003bc;M Neu5Ac, LSTa, or LSTc resulted in reduction of 14 &#x000b1; 5%, 18 &#x000b1; 4%, and 20 &#x000b1; 7% in the binding to 4A8, respectively (<xref rid="F6" ref-type="fig">Fig. 6, B and C</xref>, and fig. S3E). These results were consistent with competitive enzyme-linked immunosorbent assay (ELISA) assays, which yielded a comparable <italic toggle="yes">K</italic><sub>d</sub> in the absence of sialosides (fig. S3F), and similar reductions in 4A8 binding after incubation with the same sialosides (fig. S3G).</p><fig position="float" id="F6" fig-type="image" specific-use="distribute"><label>Fig. 6.</label><caption><title>NTD mediates SARS-CoV-2 S binding to host cell SAs.</title><p>(<bold>A</bold>) Representative sensorgram indicating binding of S&#x00394;TM trimers to the surface of sensor chips coated with the NTD-directed 4A8 antibody. The arithmetic mean of kinetic parameters of the S&#x00394;TM binding to 4A8-sensor chips was calculated from two independent experiments as described in Materials and Methods. (<bold>B</bold>) Representative SPR sensorgram showing the binding to mAb 4A8&#x02013;coated sensor chips of S&#x00394;TM trimers previously incubated with 300 &#x003bc;M of the indicated glycans. (<bold>C</bold>) Quantification of the maximum binding of mock- or glycans-treated S&#x00394;TM to the surface of 4A8-sensor chips was determined from sensorgrams like that shown in (B), and data from three independent experiments are expressed as the percentage of bound S&#x00394;TM with respect to the binding observed with mock-incubated S&#x00394;TM. Statistical significance was evaluated through parametric one-way ANOVA test, and <italic toggle="yes">P</italic> values from comparisons against the binding of mock-treated S&#x00394;TM to 4A8-sensor chips are shown.</p></caption><graphic xlink:href="sciadv.adk4920-f6" position="float"/></fig><p>These data provide additional support for the proposed SA-binding role of NTD. To further test this hypothesis, we took a mutagenesis approach. Structural data have shown that the sialoside-binding site in the NTD comprises the amino acids H69, Y145, W152, Q183, and S247. Y145 notably engages the C7-C9 glycerol side chain of sialosides, while S247 engages the NHAc-5 (<xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>). We therefore sought to eliminate these stabilizing NTD-SA interactions through expression of S&#x00394;TM bearing the amino acid changes Y145F and S247A in the NTD (NTD<sub>mut</sub>). We first validated the antigenicity of NTD<sub>mut</sub> through ELISA assays using mAb 4A8 (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>) and the RBD-directed mAbs Mab362IgA1, REGN10933, and REGN10987 (<xref rid="R58" ref-type="bibr"><italic toggle="yes">58</italic></xref>, <xref rid="R59" ref-type="bibr"><italic toggle="yes">59</italic></xref>). We detected no loss of antibody binding to NTD<sub>mut</sub> compared to wild-type S&#x00394;TM, except for REGN10987, which showed a slight, but statistically significant increase in binding to NTD<sub>mut</sub> (fig. S4A). We then evaluated the shACE2-binding properties of the NTD<sub>mut</sub> trimer through both an ELISA assay (fig. S4A), and the FCS approach described above (fig. S4B). The NTD<sub>mut</sub> trimer showed decreased shACE2 binding by ~40% compared to wild-type S&#x00394;TM in both approaches (fig. S4, A and B). Together, these findings indicate that NTD<sub>mut</sub> trimers maintain near-native antigenic properties but also allosterically reduced shACE2 binding. We then evaluated the binding of NTD<sub>mut</sub> to GSL-prepared sensor chips through SPR in the same way as described above for wild-type S&#x00394;TM (fig. S4C). The binding of the NTD<sub>mut</sub> trimer to GSL-sensor chips was reduced by 43 &#x000b1; 6% compared to the binding observed for wild-type S&#x00394;TM (fig. S4D). These data support the existence of an SA-binding site in the NTD, which involves residues Y145 and S247.</p></sec><sec disp-level="2"><title>SA allosterically modulates the RBD conformation</title><p>Our observations indicate that SARS-CoV-2 S NTD binds SA, which promotes attachment of virions to the cell surface and enhancement of ACE2 binding. We therefore investigated the mechanism governing this phenotype. We used a well-characterized smFRET imaging assay (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>, <xref rid="R60" ref-type="bibr"><italic toggle="yes">60</italic></xref>) to probe the conformational dynamics of the RBD of S&#x00394;TM in the presence of SA-containing compounds (<xref rid="F7" ref-type="fig">Fig. 7A</xref>). Application of this assay required site-specific attachment of fluorophores at positions 161 and 345 in the NTD and RBD domains, respectively. As previously described, the application of hidden Markov modeling (HMM) for analysis of the smFRET trajectories enabled identification of two FRET states (<xref rid="F7" ref-type="fig">Fig. 7B</xref>). The low-FRET state is associated with RBD in an open conformation (RBD-up), which can bind ACE2. The high-FRET state is associated with RBD in a closed conformation (RBD-down) (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>, <xref rid="R60" ref-type="bibr"><italic toggle="yes">60</italic></xref>). As expected, unbound S&#x00394;TM displayed 38 &#x000b1; 2% occupancy in the RBD-up conformation. Incubation with 0.6 &#x003bc;M shACE2 increased the RBD-up conformation occupancy to 69 &#x000b1; 2% (<xref rid="F7" ref-type="fig">Fig. 7C</xref>, fig. S5, and <xref rid="T1" ref-type="table">Table 1</xref>). Incubation of spikes with 300 &#x003bc;M Neu5Ac, LSTa, or LSTc, resulted in significant increases in the RBD-up conformation to 56 &#x000b1; 2%, 54 &#x000b1; 2%, and 65 &#x000b1; 1%, respectively (<xref rid="F7" ref-type="fig">Fig. 7C</xref>, fig. S5, and <xref rid="T1" ref-type="table">Table 1</xref>). Incubation with dextrose had no effect. These results suggest that SA compounds stabilize the RBD-up conformation.</p><fig position="float" id="F7" fig-type="image" specific-use="distribute"><label>Fig. 7.</label><caption><title>smFRET imaging reveals that SA compounds modulate SARS-CoV-2 S RBD conformation.</title><p>(<bold>A</bold>) smFRET imaging assay used to monitor RBD conformational changes (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>, <xref rid="R60" ref-type="bibr"><italic toggle="yes">60</italic></xref>). S&#x00394;TM trimers containing a single fluorescently labeled protomer were immobilized on a streptavidin-coated quartz microscope slide by way of a C-terminal polyhistidine tag and biotin&#x02013;Ni-NTA. Individual S&#x00394;TM spikes were visualized with prism-based total internal reflection fluorescence microscopy. The two known RBD conformations, RBD-down (left) and RBD-up (right), as well as covalently attached LD550 and LD650 fluorophores, are indicated. (<bold>B</bold>) Example fluorescence (top; LD550, green; LD650, red) and FRET (bottom, blue) traces acquired from an individual S&#x00394;TM trimer. Idealization (red) that results from HMM analysis is overlaid. FRET states reflective of the RBD-down and RBD-up conformations are indicated. (<bold>C</bold>) Violin plots showing the distribution of the occupancy in the RBD-up (low FRET) conformation seen in the presence of the indicated ligands. The median occupancies are indicated by the gray circle with vertical lines extending to the 25th and 75th quantiles. The mean occupancies are indicated by the horizontal lines. <italic toggle="yes">P</italic> values were determined by comparison of ligand-bound and unbound S&#x00394;TM through one-way ANOVA. (<bold>D</bold>) Violin plots indicating the RBD-up occupancies following incubation with NTD-directed mAb 4A8, an irrelevant antibody (Irr mAb), or through the sequential incubation with the indicated mAb and LSTc, displayed as in (C). <italic toggle="yes">P</italic> values were derived as in (C) from comparisons between the 4A8-incubated S&#x00394;TM and the other conditions. <italic toggle="yes">P</italic> values &#x0003c;0.05 were considered statistically significant. (<bold>E</bold>) RBD-up occupancies from NTD<sub>mut</sub> trimers in the presence or absence of the indicated ligands, shown as in (C) and (D). <italic toggle="yes">P</italic> values were derived as in (C) from comparisons unbound NTD<sub>mut</sub> and those incubated with the indicated ligands. The corresponding histograms of FRET values are shown in fig. S5, and the numeric data are reported in <xref rid="T1" ref-type="table">Table 1</xref>.</p></caption><graphic xlink:href="sciadv.adk4920-f7" position="float"/></fig><table-wrap position="float" id="T1"><label>Table 1.</label><caption><title>FRET-state occupancies and rate constants for SARS-CoV-2 S&#x00394;TM.</title></caption><table frame="hsides" rules="groups"><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">SARS-CoV-2 S</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Number of traces</th><th colspan="2" valign="top" align="center" scope="col" rowspan="1">FRET-state occupancies (%)</th><th colspan="2" valign="top" align="center" scope="col" rowspan="1">Rate constants (s<sup>&#x02212;1</sup>)</th></tr><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Low-FRET (0.35) RBD-up</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">High-FRET (0.65) RBD-down</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><italic toggle="yes">k</italic><sub>1</sub> (RBD-down toRBD-up)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><italic toggle="yes">k</italic><sub>&#x02212;1</sub> (RBD-uptoRBD-down)</th></tr></thead><tbody><tr><td scope="row" valign="top" align="left" rowspan="1" colspan="1">wt unbound</td><td valign="top" align="center" rowspan="1" colspan="1">184</td><td valign="top" align="center" rowspan="1" colspan="1">38 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">63 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">2.2 &#x000b1; 0.1</td><td valign="top" align="center" rowspan="1" colspan="1">3.6 &#x000b1; 0.3</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">wt + shACE2</td><td valign="top" align="center" rowspan="1" colspan="1">116</td><td valign="top" align="center" rowspan="1" colspan="1">69 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">31 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">2.5 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">1.12 &#x000b1; 0.08</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">wt + Dextrose</td><td valign="top" align="center" rowspan="1" colspan="1">134</td><td valign="top" align="center" rowspan="1" colspan="1">42 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">58 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">2.4 &#x000b1; 0.1</td><td valign="top" align="center" rowspan="1" colspan="1">3.5 &#x000b1; 0.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">wt + Neu5Ac</td><td valign="top" align="center" rowspan="1" colspan="1">137</td><td valign="top" align="center" rowspan="1" colspan="1">56 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">44 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">2.3 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">2.0 &#x000b1; 0.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">wt + LSTa</td><td valign="top" align="center" rowspan="1" colspan="1">115</td><td valign="top" align="center" rowspan="1" colspan="1">54 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">46 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">2.9 &#x000b1; 0.3</td><td valign="top" align="center" rowspan="1" colspan="1">2.5 &#x000b1; 0.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">wt + LSTc</td><td valign="top" align="center" rowspan="1" colspan="1">316</td><td valign="top" align="center" rowspan="1" colspan="1">65 &#x000b1; 1</td><td valign="top" align="center" rowspan="1" colspan="1">35 &#x000b1; 1</td><td valign="top" align="center" rowspan="1" colspan="1">2.8 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">1.52 &#x000b1; 0.09</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">wt + 4A8</td><td valign="top" align="center" rowspan="1" colspan="1">191</td><td valign="top" align="center" rowspan="1" colspan="1">42 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">58 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">2.2 &#x000b1; 0.1</td><td valign="top" align="center" rowspan="1" colspan="1">3.0 &#x000b1; 0.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">wt + 4A8 + LSTc</td><td valign="top" align="center" rowspan="1" colspan="1">144</td><td valign="top" align="center" rowspan="1" colspan="1">44 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">56 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">2.3 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">3.3 &#x000b1; 0.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">wt + Irr mAb</td><td valign="top" align="center" rowspan="1" colspan="1">157</td><td valign="top" align="center" rowspan="1" colspan="1">40 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">60 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">2.3 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">3.5 &#x000b1; 0.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">wt + Irr mAb + LSTc</td><td valign="top" align="center" rowspan="1" colspan="1">174</td><td valign="top" align="center" rowspan="1" colspan="1">64 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">36 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">3.0 &#x000b1; 0.3</td><td valign="top" align="center" rowspan="1" colspan="1">1.5 &#x000b1; 0.1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NTD<sub>mut</sub> unbound</td><td valign="top" align="center" rowspan="1" colspan="1">124</td><td valign="top" align="center" rowspan="1" colspan="1">41 &#x000b1; 1</td><td valign="top" align="center" rowspan="1" colspan="1">59 &#x000b1; 1</td><td valign="top" align="center" rowspan="1" colspan="1">3.4 &#x000b1; 0.3</td><td valign="top" align="center" rowspan="1" colspan="1">5.0 &#x000b1; 0.4</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NTD<sub>mut</sub> + shACE2</td><td valign="top" align="center" rowspan="1" colspan="1">143</td><td valign="top" align="center" rowspan="1" colspan="1">60 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">40 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">3.9 &#x000b1; 0.3</td><td valign="top" align="center" rowspan="1" colspan="1">2.8 &#x000b1; 0.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NTD<sub>mut</sub> + LSTc</td><td valign="top" align="center" rowspan="1" colspan="1">213</td><td valign="top" align="center" rowspan="1" colspan="1">41 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">59 &#x000b1; 2</td><td valign="top" align="center" rowspan="1" colspan="1">1.9 &#x000b1; 0.1</td><td valign="top" align="center" rowspan="1" colspan="1">2.7 &#x000b1; 0.2</td></tr></tbody></table></table-wrap><p>Further insights came from analysis of the kinetics of S&#x00394;TM conformational transitions. Consistent with our previous report (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>), the predominant effect of shACE2 binding was to decrease the rate of transition from the RBD-up conformation to the RBD-down conformation (<italic toggle="yes">k</italic><sub>&#x02212;1</sub>; <xref rid="T1" ref-type="table">Table 1</xref>), suggesting that shACE2 captures the RBD-up conformation after it is spontaneously achieved. Similarly, the SA-containing compounds had only a minor effect on the rate of transition from RBD-down to RBD-up (<italic toggle="yes">k</italic><sub>1</sub>). The more notable impact was on <italic toggle="yes">k</italic><sub>&#x02212;1</sub>, which decreased from 3.6 &#x000b1; 0.3 s<sup>&#x02212;1</sup> in the absence of glycan, to 2.0 &#x000b1; 0.2 s<sup>&#x02212;1</sup> in the presence of Neu5Ac (<xref rid="T1" ref-type="table">Table 1</xref>). LSTc had the most dramatic effect on <italic toggle="yes">k</italic><sub>&#x02212;1</sub>, reducing it to 1.52 &#x000b1; 0.09 s<sup>&#x02212;1</sup>, whereas LSTa reduced <italic toggle="yes">k</italic><sub>&#x02212;1</sub> to 2.5 &#x000b1; 0.2 s<sup>&#x02212;1</sup>. This kinetic analysis specifies that SA compounds primarily stabilize the RBD-up conformation and reduce transitions to the RBD-down conformation, thereby increasing exposure of the ACE2-binding site.</p><p>As previously reported, incubation of S&#x00394;TM with 4A8 modestly increased the RBD-up conformation to 42 &#x000b1; 2% (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>), whereas an irrelevant antibody had no effect (<xref rid="F7" ref-type="fig">Fig. 7D</xref>, fig. S5, and <xref rid="T1" ref-type="table">Table 1</xref>). Subsequent incubation with LSTc failed to increase the RBD-up occupancy to the extent seen in the absence of 4A8. Therefore, consistent with our SPR data indicating that 4A8 prevents NTD binding to SA, 4A8 inhibits SA-induced conformational changes in S&#x00394;TM.</p></sec><sec disp-level="2"><title>mAb 4A8 inhibits SA-mediated RBD activation</title><p>Having observed that 4A8 inhibited LSTc-induced RBD activation (<xref rid="F7" ref-type="fig">Fig. 7D</xref>), we next asked whether this has a functional impact in ACE2 binding. Whereas we observed a twofold increase in shACE2 binding to S&#x00394;TM bound to LSTc as compared to unbound S&#x00394;TM, preincubation of S&#x00394;TM with 4A8 before introduction of LSTc failed to increase shACE2 binding. Instead, we observed a decrease in shACE2 binding of 46 &#x000b1; 1% compared to untreated S&#x00394;TM (fig. S4E). Preincubation with the RBD-directed antibody REGN10987, used as a control for blocking shACE2 binding, resulted in a decrease shACE2 binding by 65 &#x000b1; 1%, as expected. Preincubation of the NTD<sub>mut</sub> trimer with LSTc or REGN10987 resulted in slight decreases in shACE2 binding of 17 &#x000b1; 2% or 46 &#x000b1; 2%, respectively, as compared to untreated NTD<sub>mut</sub> trimers (fig. S4F). Together, these data demonstrate that interruption of the SA-NTD interaction, either through treatment with 4A8 or mutagenesis, decreases S&#x00394;TM binding to ACE2. This observation suggests that SA may interact with S&#x00394;TM through mechanisms not involving the NTD, which inhibit ACE2 binding.</p><p>In agreement with these findings, conformational analysis of NTD<sub>mut</sub> performed through smFRET imaging showed that shACE2 binding activated the RBD-up conformation on the NTD<sub>mut</sub> trimer and that LSTc failed to trigger RBD conformational changes (<xref rid="F7" ref-type="fig">Fig. 7E</xref>, figs. S4G and S5, and <xref rid="T1" ref-type="table">Table 1</xref>). Together, these data indicate the relevance of NTD in allosterically activating the RBD-up conformation through interaction with SA, which facilitates engagement with ACE2 during SARS-CoV-2 entry.</p></sec></sec><sec sec-type="discussion" disp-level="1"><title>DISCUSSION</title><p>Several virus families including <italic toggle="yes">Coronaviridae</italic> exploit host glycans present on cellular membranes during early events of viral infection (<xref rid="R61" ref-type="bibr"><italic toggle="yes">61</italic></xref>, <xref rid="R62" ref-type="bibr"><italic toggle="yes">62</italic></xref>). Virus attachment to glycans on the cell surface may enable the virus to &#x0201c;surf&#x0201d; to membrane microdomains enriched in their cognate receptors (<xref rid="R63" ref-type="bibr"><italic toggle="yes">63</italic></xref>). In the case of SARS-CoV-2, host glycans on the plasma membrane are a determinant of virion attachment to the cell surface (<xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>). Here, we investigated the relationship between sialoside glycans and ACE2 binding to SARS-CoV-2 S during virion attachment to the cell surface. Overall, our findings demonstrate that S binding to SA can mediate attachment to the cell surface in the absence of ACE2. In the presence of ACE2, interaction of S with cell-surface SA moieties resulted in biphasic binding of pseudovirions to cells with peak binding occurring at 150 &#x003bc;M SA (<xref rid="F2" ref-type="fig">Fig. 2C</xref>). The increase in ACE2 binding results from sialoside glycans binding to the NTD and allosterically stabilizing the S conformation in which the RBD is up and the ACE2-binding site is exposed. Similar biphasic binding of influenza A virions to the GD1a ganglioside in the presence of orthogonal SA compounds has also been reported (<xref rid="R64" ref-type="bibr"><italic toggle="yes">64</italic></xref>).</p><p>A previous report indicated that interaction of SARS-CoV-2 S RBD with the proteoglycan heparin, which has subunits of glycosaminoglycans formed by <sc>d</sc>-glucuronic acid &#x003b2;1&#x02013;4 linked to <italic toggle="yes">N</italic>-acetyl-<sc>d</sc>-glucosamine (<xref rid="R65" ref-type="bibr"><italic toggle="yes">65</italic></xref>), increased ACE2 binding (<xref rid="R31" ref-type="bibr"><italic toggle="yes">31</italic></xref>). Structural analysis suggested that heparin directly promotes the open conformation of RBD, thus facilitating the binding to ACE2 (<xref rid="R31" ref-type="bibr"><italic toggle="yes">31</italic></xref>). The present results elucidate an additional complementary role for host glycans in promoting virus attachment to the cell surface&#x02014;here through an allosteric mechanism&#x02014;and increasing subsequent binding to ACE2. Notably, a recent structural study of the HKU1 coronavirus spike demonstrated that binding of a sialoglycan to the S1<sup>A</sup> domain, homologous to NTD, promoted a conformation in which the S1<sup>B</sup> domain, homologous to the RBD, had transitioned to an up conformation (<xref rid="R66" ref-type="bibr"><italic toggle="yes">66</italic></xref>). This study reported the observation of an RBD-up conformation in the HKU1 spike and suggests a similar allosteric mechanism to that supported by our data for the SARS-CoV-2 spike. Further studies are needed to elucidate the generality of this mechanism in other coronaviruses. Allosteric activation of influenza virus hemagglutinin (HA) by SA has also been reported. Treatment of HA with liposomes containing the GD1a ganglioside or soluble LSTa induced conformational changes in the fusion peptide, which resides more than 100 &#x000c5; from the SA-binding site (<xref rid="R67" ref-type="bibr"><italic toggle="yes">67</italic></xref>). These observations indicated that SA binding to HA allosterically stimulates conformational changes that promote membrane fusion and virus entry. Whether SA binding to S promotes analogous conformational changes in the S2 domain will require future investigations. While the present observations only report on RBD motions that result from NTD-SA interaction, the subsequent enhancement of ACE2 binding to the RBD may in turn increase exposure of the TMPRSS2 cleavage site (<xref rid="R68" ref-type="bibr"><italic toggle="yes">68</italic></xref>, <xref rid="R69" ref-type="bibr"><italic toggle="yes">69</italic></xref>). In this way, SA binding to the NTD may indirectly contribute to the activation of the fusogenic activity of S (<xref rid="R19" ref-type="bibr"><italic toggle="yes">19</italic></xref>). These studies collectively support a model in which viral envelope glycoproteins sense cues at the cell surface that promote downstream events in virus entry.</p><p>The neutralizing mAb 4A8, which targets the NTD, allosterically modulates S1/S2 cleavage and blocks S-mediated membrane fusion (<xref rid="R19" ref-type="bibr"><italic toggle="yes">19</italic></xref>). Similarly, the NTD-directed mAb 7G7 inhibited access of furin-like proteases to the S1/S2 cleavage site, preventing cleavage and reducing infectivity (<xref rid="R20" ref-type="bibr"><italic toggle="yes">20</italic></xref>). Our data suggest that this class of antibodies also prevents NTD-SA interactions. Analysis of S structures in complex with 4A8 or SA indicate that the 4A8- and SA-binding sites do not overlap (<xref rid="F8" ref-type="fig">Fig. 8</xref>). Instead, binding of 4A8 to the NTD leads to localized conformational changes that reorient NTD residues Y145, Q183, and S247. In the SA-bound structure, these residues form stabilizing electrostatic interactions with SA. Blocking NTD-SA interactions then has the combined effect of inhibiting SA-mediated virus attachment to the cell surface, as well as reducing SA-promoted exposure of the ACE2-binding site. In this way, the data presented here contribute understanding to the mechanism of neutralization by NTD-targeting mAbs (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>, <xref rid="R70" ref-type="bibr"><italic toggle="yes">70</italic></xref>, <xref rid="R71" ref-type="bibr"><italic toggle="yes">71</italic></xref>).</p><fig position="float" id="F8" fig-type="image" specific-use="distribute"><label>Fig. 8.</label><caption><title>Binding of 4A8 mAb to SARS-CoV-2 S NTD indirectly prevents SA binding.</title><p>(<bold>A</bold>) Aligned structures of the trimeric S ectodomain determined in complex with the antigen-binding fragment of 4A8 [cyan cartoon rendering; PDB 7C2L (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>)] or sialyllactose (only the SA moiety is shown in yellow) [gray, PDB 7QUR (<xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>)]. Two protomers in the trimer are displayed in gray surface rendering. RBD and NTD domains are indicated, with the NTD highlighted in a box. (<bold>B</bold>) Expanded view of the NTD bound to 4A8 (cyan) or SA (gray, with SA in yellow). (<bold>C</bold>) Further expanded view of the 4A8 and SA binding interfaces, which do not overlap. NTD residues Y145, Q183, and S247, which form the SA-binding site are indicated. These residues are rearranged in the presence of 4A8, leading to loss of the SA-binding site.</p></caption><graphic xlink:href="sciadv.adk4920-f8" position="float"/></fig><p>The relationship between S sequence variation and glycan binding requires further investigation. Structural analysis of the NTD suggested four sugar-binding sites (<xref rid="R72" ref-type="bibr"><italic toggle="yes">72</italic></xref>), including the sialoside-binding pocket previously proposed (<xref rid="R39" ref-type="bibr"><italic toggle="yes">39</italic></xref>). Mutations in the NTD of the Omicron variant increased the predicted SA-binding energy compared to the original Wuhan-1 strain, which may contribute to the increased transmission of the Omicron lineage (<xref rid="R72" ref-type="bibr"><italic toggle="yes">72</italic></xref>). However, nuclear magnetic resonance experiments demonstrated that spikes from the Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529) strains have depleted binding to &#x003b1;2,3-linked sialosides as compared to that observed for the Wuhan-1 strain (<xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>). It remains to be explored whether the putative glycan-binding pockets in the NTD from SARS-CoV-2 variants can bind other glycans and whether they modulate conformational changes in S. Nevertheless, it is interesting that variant spikes have both deletions and multiple point mutations in the NTD, which may affect glycan binding (<xref rid="R73" ref-type="bibr"><italic toggle="yes">73</italic></xref>, <xref rid="R74" ref-type="bibr"><italic toggle="yes">74</italic></xref>). In the present study, S containing mutations Y145F and S247A in the NTD had decreased occupancy in the RBD-up conformation (figs. S4F and S5 and <xref rid="T1" ref-type="table">Table 1</xref>) and reduced shACE2 binding (fig. S4, A and B) compared to wild type. This observation suggests a relevant and functional role for the NTD in regulating the binding to ACE2. In addition, the RBD equilibrium evolved to predominantly adopt the up conformation (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>&#x02013;<xref rid="R25" ref-type="bibr"><italic toggle="yes">25</italic></xref>, <xref rid="R75" ref-type="bibr"><italic toggle="yes">75</italic></xref>). This may be evidence that the variant spikes rely less on activation of the RBD by the NTD binding to SA. Consequently, this could provide the variants with the ability to directly bind ACE2 while at the same time evading neutralizing antibodies targeting the NTD (<xref rid="R16" ref-type="bibr"><italic toggle="yes">16</italic></xref>, <xref rid="R76" ref-type="bibr"><italic toggle="yes">76</italic></xref>&#x02013;<xref rid="R82" ref-type="bibr"><italic toggle="yes">82</italic></xref>). Similarly, the evolution of additional positive charge in the RBD may increase binding to cell-surface heparan-sulfate proteoglycans, further reducing the dependence on NTD-SA interactions (<xref rid="R83" ref-type="bibr"><italic toggle="yes">83</italic></xref>).</p><p>Overall, the results presented here, together with previous observations of other viral fusion proteins (<xref rid="R31" ref-type="bibr"><italic toggle="yes">31</italic></xref>, <xref rid="R66" ref-type="bibr"><italic toggle="yes">66</italic></xref>, <xref rid="R67" ref-type="bibr"><italic toggle="yes">67</italic></xref>), support a model for early interactions between virions and cells where host glycans play a fundamental role in the allosteric activation of viral spike proteins. This allosteric control results in conformational changes that promote receptor binding and membrane fusion. Future studies will explore the generality of this concept in other virus families.</p></sec><sec sec-type="materials|methods" disp-level="1"><title>MATERIALS AND METHODS</title><sec disp-level="2"><title>Cell culture</title><p>ExpiCHO-S cells (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) were cultured in ExpiCHO expression media (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) at 37&#x000b0;C, 8% CO<sub>2</sub> with orbital shaking according to the manufacturer instructions. HEK-293T cells were obtained from American Type Culture Collection (Manassas, VA, USA). HEK-293T cells expressing human ACE2 [293T-ACE2, BEI Resources, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), catalog no. NR-52511] (<xref rid="R84" ref-type="bibr"><italic toggle="yes">84</italic></xref>) were provided by T. Morrison (UMass Chan Medical School). HEK-293T cells expressing both ACE2 and TMPRSS2 [293T-ACE2.TMPRSS2 (mCherry), catalog no. NR-55293] (<xref rid="R48" ref-type="bibr"><italic toggle="yes">48</italic></xref>), were obtained from BEI Resources (NIAID, NIH). All the HEK-293T cell lines used were cultured at 37&#x000b0;C and 5% CO<sub>2</sub> in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM, Gibco, Thermo Fisher Scientific, Whaltham, MA, USA), supplemented with 10% (v/v) fetal bovine serum (BenchMark, GeminiBio, Sacramento, CA, USA), penicillin (100 U/ml), streptomycin (100 &#x003bc;g/ml), and 1 mM glutamine (Gibco, Thermo Fisher Scientific, Waltham, MA, USA).</p></sec><sec disp-level="2"><title>Plasmids and site-directed mutagenesis</title><p>Molecular clones of the heavy and light chains of the anti&#x02013;HIV-1 Env mAb 17b (<xref rid="R85" ref-type="bibr"><italic toggle="yes">85</italic></xref>), used in this study as an irrelevant antibody, were provided by P. Kwong (NIAID, NIH). The pNL4-3.Luc.R-E- plasmid was obtained from the NIH AIDS reagent program (catalog ARP-3418) (<xref rid="R86" ref-type="bibr"><italic toggle="yes">86</italic></xref>). An <italic toggle="yes">ochre</italic> stop codon was introduced into the <italic toggle="yes">tat</italic> gene as described (<xref rid="R87" ref-type="bibr"><italic toggle="yes">87</italic></xref>). The plasmid encoding the HIV-1 GagPol under the control of the cytomegalovirus promotor has been described previously (<xref rid="R88" ref-type="bibr"><italic toggle="yes">88</italic></xref>), while the replication-deficient molecular clone HIV-1 NL4-3 Gag-iGFP &#x00394;Env (<xref rid="R89" ref-type="bibr"><italic toggle="yes">89</italic></xref>) was provided by B. K. Chen (Icahn School of Medicine at Mount Sinai, NY). The plasmid pMM310-Myc (catalog no. 80053) encoding a Myc-tagged version of the BlaM-HIV-1 Vpr fusion protein (Myc-BlaM-Vpr) (<xref rid="R90" ref-type="bibr"><italic toggle="yes">90</italic></xref>) was obtained from Addgene (Watertown, MA, USA). The full-length SARS-CoV-2 S expression plasmid used to produce S-pseudotyped viruses has been previously described (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>). Both expression vectors bearing human immunoglobulin G1 (IgG1) heavy-chain (hIgG1) and kappa light-chain Fc fragments (hIgKappa) (<xref rid="R91" ref-type="bibr"><italic toggle="yes">91</italic></xref>) for cloning of recombinant antibodies were provided by M. C. Nussenzweig (The Rockefeller University, New York, NY, USA). To generate a molecular clone of mAb 4A8, heavy and light variable (VL) region sequences (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>) were synthesized (GeneScript USA Inc., Piscataway, NJ, USA) and cloned in-frame with hIgG1 heavy or hIgKappa light chain in the above expression vectors (<xref rid="R91" ref-type="bibr"><italic toggle="yes">91</italic></xref>) through AgeI/SalI or AgeI/BsiWI restriction sites, respectively. The synonymous nucleotide change C174T was included in the synthetic VL sequence to remove an AgeI restriction site and to facilitate its subcloning into the hIgKappa vector. SARS-CoV-2 S and S&#x00394;TM expressors have been described before (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>, <xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). Mutations Y145F and S247A were introduced into S&#x00394;TM expressors (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>) using the primers Y145F-R (aggaaggggtcattgcaaaattggaattc), Y145F-F (gggcgtgtacttccataagaacaacaagtcttgg), S247A-R (ccagcagggtctggaaccgg), and S247A-F (ccctgcacagagcctatctgacccccggcgattc) in mutagenic polymerase chain reactions using the Q5 Site-Directed Mutagensis Kit (NEB, Ipswich, MA, USA) according to the manufacturer&#x02019;s instructions. Site-directed mutagenesis was confirmed through Sanger sequencing (GENEWIZ, Walthman, MA, USA).</p></sec><sec disp-level="2"><title>Antibodies, recombinant proteins, and soluble glycans</title><p>mAbs 4A8 and 17b were expressed in ExpiCHO-S cells by cotransfection of recombinant constructs bearing their respective heavy and light chains at 1:2 ratio using the ExpiFectamine CHO transfection kit (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer&#x02019;s instructions. Both antibodies were purified from the cell culture supernatant 12 days after transfection through protein G affinity resin (Thermo Fisher Scientific, Waltham, MA, USA) and prepared as previously described (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). Human mAbs Mab362IgA1, REGN10933, and REGN10987 were previously prepared (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). Mouse mAbs anti&#x02013;HIV-1-p24 (anti-p24, catalog no. GTX41618) and 1A9 anti&#x02013;SARS-CoV-2 S2 (catalog no. GTX632604) were purchased from Genetex (Irvine, CA, USA). Anti&#x02013;Myc-tag mouse mAb (catalog no. A00704-100) was purchased from GenScript (Piscataway, NJ, USA). Both horseradish peroxidase (HRP)&#x02013;conjugated anti-human IgG Fc and anti-mouse IgG Fc were purchased from Invitrogen (Waltham, MA, USA). HRP-conjugated anti-human kappa antibody (catalog no. 2060-05) was purchased from SouthernBiotech (Birmingham, AL, USA), while both rabbit anti-ACE2 antibody (catalog no. ab108252) and goat anti-rabbit IgG antibody conjugated to HRP (catalog no. ab205718) were gotten from Abcam (Cambridge, UK). Expression, purification, and preparation of SARS-CoV-2 S ectodomain S&#x00394;TM trimers, shACE2, and their fluorescent versions for biochemical, FCS, and smFRET assays have been previously described (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). The lectin SNA and the recombinant nonglycosylated HIV-1 gp120 polypeptide chain were purchased from Vector Laboratories (Newark, CA, USA) and Abcam (Cambridge, UK), respectively. <italic toggle="yes">N</italic>-acetylneuraminic acid (Neu5Ac) and dextrose (<sc>d</sc>-glucose) were purchased from MP Biomedicals LLC (Irvine, CA, USA) and J. T. Baker Avantor (Radnor, PA, USA) respectively. GSL, the LSTa, and LSTc were purchased from Dextra Laboratories (Reading, UK).</p></sec><sec disp-level="2"><title>Virus production</title><p>HIV-1&#x02013;pseudotyped viruses based on three different nonreplicative NL4-3 provirus molecular clones were produced as follows. SARS-CoV-2 S pseudoviruses for infectivity assays based on the luciferase activity reporter were produced by cotransfecting HEK-293T cells with a 3:1 mass ratio of plasmid pNL4-3.Luc.R-E- <italic toggle="yes">tat</italic>_ochre to Wuhan-Hu-1 SARS-CoV-2 S expressor plasmid (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>) using polyethylenimine (PEI &#x0201c;MAX,&#x0201d; Polysciences, Warrington, PA) at a PEI:DNA mass ratio of 5:1. Fluorescent and nonreplicative S pseudoviruses for cell-binding assays were produced by cotransfecting cells with the plasmid pNL4-3 Gag-iGFP &#x00394;Env (<xref rid="R89" ref-type="bibr"><italic toggle="yes">89</italic></xref>) and the above SARS-CoV-2 S expressor using the above-described PEI:DNA ratio. Nonreplicative SARS-CoV-2 S pseudoviruses used to evaluate viral fusion and cell entry assays were produced by cotransfection of the above SARS-CoV-2 S expressor together with plasmids encoding the HIV-1 GagPol (<xref rid="R88" ref-type="bibr"><italic toggle="yes">88</italic></xref>) and Myc-BlaM-Vpr (<xref rid="R90" ref-type="bibr"><italic toggle="yes">90</italic></xref>) in a ratio of 1:1:1. For all three varieties of pseudovirions, bald particles lacking SARS-CoV-2 S were produced and used as negative controls in their respective approaches. In all cases, cells were washed 6 hours after transfection and incubated with fresh complete DMEM for an additional 64 hours. Viral supernatants were harvested and centrifuged at 4000<italic toggle="yes">g</italic> at room temperature, followed by passage through a 0.45-&#x003bc;m low protein&#x02013;binding filter. Viruses for infectivity assays (luciferase activity reporter) were concentrated by ultracentrifugation at the maximum <italic toggle="yes">g</italic>-force of 107,100<italic toggle="yes">g</italic> for 2 hours at 4&#x000b0;C, while virus preparations for cell binding and cell entry (BlaM-based) assays were similarly utracentrifuged through a 10% sucrose cushion. Viral pellets for infectivity and for cell entry assays were resuspended in regular or phenol red-free DMEM (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) respectively, while those for cell-binding assays were resuspended in Dulbecco&#x02019;s phosphate-buffered saline (DPBS; Gibco, Thermo Fisher Scientific, Waltham, MA, USA). The HIV-1 p24 protein content of all the virus preparations was determined by using the Lenti-X p24 Rapid Titer Kit (Takara Bio USA Inc., San Jose, CA, USA) according to the manufacturer&#x02019;s indications. Virus preparations were aliquoted and stored at &#x02212;80&#x000b0;C until use.</p></sec><sec disp-level="2"><title>Immunoblots</title><p>Proteins of interest were detected in the indicated virus preparations through immunoblot assays as follows. Viral samples were mixed with 4&#x000d7; Laemmli sample buffer (Bio-Rad, Hercules, CA, USA) supplemented with 2-mercaptoethanol (Fisher Chemical, Hampton, NH, USA), heated for 5 min at 98&#x000b0;C, and proteins were resolved by denaturing polyacrylamide gel electrophoresis using 4 to 20% acrylamide gels (Bio-Rad, Hercules, CA, USA). Protein gels were then transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) according to the manufacturer&#x02019;s instructions. After blocking for 1 hour at room temperature with 5% (w/v) skim milk in PBS-T buffer [PBS and 0.1% (v/v) Tween-20, Thermo Fisher Scientific, Hampton, NH, USA], membranes were incubated by shaking overnight at 4&#x000b0;C with the indicated primary antibodies diluted in blocking buffer. Specific detection of SARS-CoV-2 S, its S2 subunit, and HIV-1 p24 protein was achieved by using dilutions of 1/2000 of murine mAbs (GeneTex, Irvine, CA, USA) 1A9 (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>) and anti-p24, respectively, while a mouse monoclonal anti-Myc tag antibody (GenScript, Piscataway, NJ, USA) diluted 1/5000 was used to detect the Myc-tagged BlaM-HIV-1 Vpr fusion protein. After incubation with primary antibodies, membranes were washed three times with PBS-T and then incubated with HRP-conjugated anti-mouse IgG (Invitrogen, Waltham, MA, USA) diluted in 0.5% (w/v) skim milk/PBS-T for 1 hour at room temperature. After three washes with PBS-T, membranes were developed using SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer&#x02019;s instructions.</p></sec><sec disp-level="2"><title>Virus cell entry and infectivity assays</title><p>The effect of SA treatment on viral cell entry and infectivity was evaluated through two different approaches. First, infectivity assays were performed using 293T-ACE2.TMPRSS2 cells because cell expression of TMPRSS2 makes more efficient virus cell entry (<xref rid="R48" ref-type="bibr"><italic toggle="yes">48</italic></xref>, <xref rid="R92" ref-type="bibr"><italic toggle="yes">92</italic></xref>, <xref rid="R93" ref-type="bibr"><italic toggle="yes">93</italic></xref>) and pseudovirions bearing a luciferase gene reporter based on a described method (<xref rid="R84" ref-type="bibr"><italic toggle="yes">84</italic></xref>) with minor modifications. In brief, 2.0 &#x000d7; 10<sup>5</sup> 293T-ACE2.TMPRSS2 cells per well were seeded 16 hours before the assay in 24-well plates previously treated with poly-<sc>l</sc>-lysine solution (0.1 mg/ml; MilliporeSigma, Burlington, MA, USA) to improve cell adherence and prevent cell disruption (<xref rid="R84" ref-type="bibr"><italic toggle="yes">84</italic></xref>). Before infectivity assays, cells were washed twice with MEM, and treated or not with <italic toggle="yes">Arthrobacter ureafaciens</italic> NA (40 mU/ml; MilliporeSigma, Burlington, MA, USA) for 2 hours at 37&#x000b0;C to remove terminal SAs from the cell surface (<xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>, <xref rid="R47" ref-type="bibr"><italic toggle="yes">47</italic></xref>, <xref rid="R54" ref-type="bibr"><italic toggle="yes">54</italic></xref>, <xref rid="R94" ref-type="bibr"><italic toggle="yes">94</italic></xref>, <xref rid="R95" ref-type="bibr"><italic toggle="yes">95</italic></xref>). Cells were then washed twice before 50 ng p24 per well of S pseudoviruses or bald particles (negative control) were diluted in the MEM and were adsorbed on cells for 3 hours at 37&#x000b0;C. When indicated, viruses were incubated with different concentrations of shACE (0 to 1.4 &#x003bc;M) or with 0 to 1.5 mM of dextrose, Neu5Ac, LSTa, LSTc, or the indicated combinations, for 1 hour at 37&#x000b0;C before viral adsorption. Viral inoculums were then removed, cells were washed twice, and fresh complete DMEM was added. Infected cells were washed with DPBS 72 hours after infection and lysed with Glo lysis buffer (Promega, Madison, WI, USA) according to the manufacturer&#x02019;s instructions. Luciferase activity in cell lysates was detected by mixing equal volumes of lysate and Steady-Glo luciferase assay system reagent (Promega, Madison, WI, USA) and measuring luminescence on a Synergy H1 microplate reader (Biotek, Winooski, VT). Luminescence signal from mock-infected cells lysates was subtracted from the signal obtained from infected cells. Infectivity was expressed as the percentage of that seen in cells inoculated with untreated virus.</p><p>In the second approach, the viral membrane fusion and cell entry of pseudovirions was assayed using a BlaM-based enzymatic assay (<xref rid="R52" ref-type="bibr"><italic toggle="yes">52</italic></xref>) with minor modifications. Briefly, 2.5 &#x000d7; 10<sup>5</sup> 293T-ACE2.TMPRSS2 cells per well were grown in 96-well plates with phenol red&#x02013;free DMEM for 24 hours. Before virus inoculation, cells were treated or not with NA as indicated above. Viruses were treated with the indicated glycans as described above or with 125 nM of either the mAb 1A9 or 17b [used as irrelevant (Irr) antibody]. Cells treated with NA were put on ice for 3 min. Medium was removed, and pseudovirus equivalent to 75 ng p24 was adsorbed on cells by spinoculation at 2095<italic toggle="yes">g</italic>, 4&#x000b0;C, for 30 min (<xref rid="R52" ref-type="bibr"><italic toggle="yes">52</italic></xref>). Cells were washed with cold DMEM to remove unbound virus. Fusion and viral entry were allowed to proceed by shifting the cells to 37&#x000b0;C. After 90 min, cells were chilled briefly by placing 96-w plates on ice, loaded with CCF4-AM fluorophore (LiveBLAzer FRET&#x02014;B/G Loading Kit, Invitrogen, Waltham, MA, USA) in the presence of 2.5 mM probenecid (Alfa Aesar, Haverhill, MA, USA), and incubated for 16 hours at 12&#x000b0;C. Detection of the CCF4-AM cleavage by Myc-BlaM-Vpr, as a result of cell entry (<xref rid="R52" ref-type="bibr"><italic toggle="yes">52</italic></xref>), was determined using a Synergy H1 microplate reader (Biotek, Winooski, VT, USA) according to the manufacturer of the LiveBLAzer FRET&#x02014;B/G Loading kit (Invitrogen, Waltham, MA, USA). Virus entry was expressed as the percentage of that seen for untreated pseudovirus in mock NA&#x02013;treated cells.</p></sec><sec disp-level="2"><title>Virus cell&#x02013;binding assays</title><p>The binding of fluorescent SARS-CoV-2 S&#x02013;pseudoviruses was evaluated in HEK293T (293T) cells lacking ACE2 expression, or to the HEK-293T-hACE2 cell line that stably expresses human ACE2 but not TMPRSS2, to discard any potential implications of this protease in virus binding (<xref rid="R96" ref-type="bibr"><italic toggle="yes">96</italic></xref>). For this, 2.5 &#x000d7; 10<sup>5</sup> cells per well were seeded 24 hours before the assay in flat bottom clear, white polystyrene 96-well plates (Corning, Kennebunk, ME, USA) previously treated with poly-<sc>l</sc>-lysine solution (MilliporeSigma, Burlington, MA, USA) as above indicated. When indicated, fluorescent S pseudoviruses were incubated or not with the above-indicated concentrations of shACE, the indicated glycans (dextrose, Neu5Ac, LSTa, or LSTc), 625 nM of either the NTD-directed mAb 4A8 or the 17b (Irr) mAb, or the indicated combination of them, for 1 hour at 37&#x000b0;C before viral adsorption. Both fluorescent S pseudoviruses (50 ng p24 per well) or bald viral particles used as negative control, were absorbed for 3 hours on cells previously treated or not with NA as above indicated and set on an ice bath to prevent virus-cell internalization. Viral mixes were then removed, and cells were quickly washed twice with cold DPBS and fixed with cold 2% (v/v) formaldehyde (Sigma-Aldrich, St. Louis, MO, USA) in DPBS for 20 min while kept on the ice bath. Fixed cell monolayers were then washed twice with cold DPBS, and their fluorescence (emission at 530 nm) was determined using a Synergy H1 microplate reader (Biotek, Winooski, VT) through excitation at 485 nm. Fluorescence signal from bald virus absorbed on cells was subtracted from those gotten with S pseudovirus, and the virus binding was expressed as the percent of virus-cell binding gotten with untreated S pseudovirus, which represents 100% of binding in the indicated cell lines.</p></sec><sec disp-level="2"><title>FCS-based ACE2-binding assay</title><p>ACE2 binding to untagged S&#x00394;TM spikes was evaluated by FCS as described (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>) with minor modifications. Briefly, 50 nM S&#x00394;TM was preincubated or not with 150 nM of the indicated antibody for 1 hour before being incubated with the indicated glycan concentration in PBS (pH 7.5) (Thermo Fisher Scientific, Waltham, MA, USA) for 30 min, followed by additional incubation with 100 nM Cy5-labeled shACE2 for 1 hour at room temperature. Samples were then placed on no. 1.5 coverslips (ThorLabs, Newton, NJ, USA) and mounted on a CorTector SX100 (LightEdge Technologies, Beijing, China) equipped with a 638-nm laser. Twenty to twenty-five autocorrelation measurements per independent experiment were made for 10 s each at room temperature. Fractions of unbound and bound (<italic toggle="yes">f</italic>) shACE2 after incubation with S&#x00394;TM were obtained from normalized autocorrelation curves fitted to a model of the diffusion of two species in a three-dimensional Gaussian confocal volume (<xref rid="R97" ref-type="bibr"><italic toggle="yes">97</italic></xref>, <xref rid="R98" ref-type="bibr"><italic toggle="yes">98</italic></xref>)<disp-formula><mml:math id="m1" display="block" overflow="scroll"><mml:mi>G</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">&#x003c4;</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>f</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x000b7;</mml:mo><mml:msub><mml:mi>g</mml:mi><mml:mtext>unbound</mml:mtext></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">&#x003c4;</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>f</mml:mi><mml:mo>&#x000b7;</mml:mo><mml:msub><mml:mi>g</mml:mi><mml:mtext>bound</mml:mtext></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">&#x003c4;</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:math></disp-formula>where<disp-formula><mml:math id="m2" display="block" overflow="scroll"><mml:msub><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">&#x003c4;</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo mathvariant="italic">=</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi mathvariant="normal">&#x003c4;</mml:mi><mml:msub><mml:mi mathvariant="normal">&#x003c4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="italic">&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mi mathvariant="normal">&#x003c4;</mml:mi><mml:mrow><mml:msup><mml:mi>s</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:msub><mml:mi mathvariant="normal">&#x003c4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="italic">&#x02212;</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></disp-formula>and &#x003c4;<italic toggle="yes"><sub>i</sub></italic> is the diffusion time for bound or unbound shACE2 and <italic toggle="yes">s</italic> is the structure factor that parameterizes the dimensions of the confocal volume. shACE2 binding was expressed as the average fraction (<italic toggle="yes">f</italic>) bound to S&#x00394;TM in the presence of the indicated concentrations of glycans with respect to the fraction bound in the absence of glycans (<xref rid="F3" ref-type="fig">Fig. 3</xref>). All fitting was performed with a nonlinear least-squares algorithm (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>) in MATLAB (The MathWorks, Waltham, MA, USA) (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>).</p></sec><sec disp-level="2"><title>ELISA assays</title><p>Competitive binding to the NTD of SARS-CoV-2 S of mAb 4A8 and the indicated glycans was evaluated with ELISA assays as previously described (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). Briefly, 96-well polystyrene plates (Thermo Fisher Scientific, Waltham, MA, USA) were coated either with 200 ng of SARS-CoV-2 S&#x00394;TM protein or bovine serum albumin (BSA, Thermo Fisher Scientific, Waltham, MA, USA) overnight at 4&#x000b0;C. Plates were washed three times with PBS and blocked for 1 hour at room temperature with 5% (w/v) skim milk in PBS-T. After three washes with PBS, plates were incubated for 2 hours at room temperature with 625 nM of 4A8 mAb together with the indicated concentrations of dextrose, Neu5Ac, LSTa, or LSTc (fig. S3). Incubation with 10 nM of shACE2, or antibodies 4A8, MAb362IgA1, REGN10933, and REGN10987, were used to evaluate binding of NTD<sub>mut</sub> spike to the soluble monomeric receptor through a sandwich ELISA assay, or its antigenicity through direct ELISA assays, respectively. Rabbit-monoclonal anti-ACE2 antibody (ab108252, abcam, Cambridge, UK) diluted 1:1000 in PBS was used to detect shACE2 bound to spikes. After three washes, the secondary antibody HRP-conjugated anti-human IgG Fc (Invitrogen, Waltham, MA, USA) diluted 1:10,000 in PBS was used in wells treated with 4A8, REG10933, and REG10987 antibodies for 1 hour at 37&#x000b0;C, while HRP-conjugated anti-human kappa antibody (SouthernBiotech, Birmingham, AL, USA) diluted 1:4000 or HRP-conjugated anti-rabbit IgG (Abcam, Cambridge, UK) diluted 1:50,000 in PBS were used to detect Mab362IgA1 or anti-ACE2 antibodies, respectively, and developed with 1-Step Ultra TBM-ELISA (Thermo Fisher Scientific, Waltham, MA, USA) reagent according to the manufacturer&#x02019;s instructions. The absorbances at 450 nm were measured using a Synergy H1 microplate reader (BioTek, Winooski, VT). Absorbance values from nonspecific binding to BSA-coated wells were subtracted from the values obtained for S&#x00394;TM-coated wells, and results were expressed as the percent of 4A8 bound to S&#x00394;TM seen without glycan coincubation.</p></sec><sec disp-level="2"><title>SPR assays</title><p>Binding kinetics and affinities of the lectin SNA for GSL and of S&#x00394;TM for GSL and mAb 4A8 (fig. S3) were assessed through SPR using a Nicoya OpenSPR-XT instrument (Nicoya, Kitchener, ON, Canada). Capture surfaces were prepared by covalent immobilization of GSL or mAb 4A8 on carboxyl sensor chips (Nicoya, Kitchener, ON, Canada) using an Amine Coupling Kit (Nicoya, Kitchener, ON, Canada) according to the instructions of the manufacturer. After the mAb 4A8 or GSL immobilization procedure, the average resonance unit (RU) signals of 1.5 &#x000b1; 0.2 &#x000d7; 10<sup>3</sup> and 3.6 &#x000b1; 0.5 &#x000d7; 10<sup>1</sup> RU were achieved respectively. The indicated dilutions of SNA or S&#x00394;TM (fig. S3) were prepared in PBS-T and injected for 5 min at a flow rate of 20 to 50 &#x003bc;l/min with a dissociation phase of 4.5 to 10 min in PBS-T at 20&#x000b0;C. Injections of 10 mM glycine (pH 2.5) at a flow rate of 150 &#x003bc;l/min, resulting in 40 s of contact time, were used to regenerate 4A8-coated surfaces between the injections of analyte. Injections of 100 mM glycine (pH 1.7) were similarly used to regenerate respectively GSL-coated sensor surfaces (<xref rid="R56" ref-type="bibr"><italic toggle="yes">56</italic></xref>). In both cases, 4.5 min of flow at 150 &#x003bc;l/min of PBS-T was used to reequilibrate sensor surfaces. We assessed the nonspecific binding of S&#x00394;TM and SNA to the GSL-coated sensor surfaces by comparison to an irrelevant recombinant nonglycosylated protein covalently immobilized on carboxyl sensors using the same SPR running parameters. When indicated, 10 nM S&#x00394;TM was incubated with 600 nM of mAb 4A8 or the irrelevant mAb 17b for 1 hour at room temperature before injection into the SPR instrument to evaluate the maximum S&#x00394;TM binding to GSL-coated sensor surfaces (<xref rid="F5" ref-type="fig">Fig. 5A</xref>). Similarly, to evaluate the maximum binding to 4A8-prepared sensor chips, 5 nM S&#x00394;TM was incubated with 300 &#x003bc;M (<xref rid="F5" ref-type="fig">Fig. 5C</xref>) dextrose, Neu5Ac, LSTa, or LSTc before injection into the SPR instrument. Two independent experiments were performed with SNA and S&#x00394;TM under each indicated condition. Kinetic parameters were obtained by fitting the corrected data to a 1:1 binding model using TraceDrawer software v1.9.1 (Ridgeview Instruments AB, Uppsala, Sweden). The association rate constant (<italic toggle="yes">k</italic><sub>on</sub>) was determined by fitting the binding of the analyte (SNA or S&#x00394;TM) at each concentration. The dissociation rate constant (<italic toggle="yes">k</italic><sub>off</sub>) was determined by fitting the change in the binding response during both the association and the dissociation phases. The equilibrium <italic toggle="yes">K</italic><sub>d</sub> was calculated from the ratio of <italic toggle="yes">k</italic><sub>on</sub> to <italic toggle="yes">k</italic><sub>off</sub>. When indicated, maximum S&#x00394;TM binding values were obtained using the above software and the corresponding data (<xref rid="F5" ref-type="fig">Figs. 5B</xref> and <xref rid="F6" ref-type="fig">6B</xref> and figs. S3, C and E, and S4C). Results were plotted (<xref rid="F5" ref-type="fig">Figs. 5C</xref> and <xref rid="F6" ref-type="fig">6C</xref> and fig. S4D) using GraphPad Prism version 9.2.0 (GraphPad Software, San Diego, CA, USA). Data are expressed as the percent of S&#x00394;TM bound to the indicated sensor compared to the level of binding observed in the control condition.</p></sec><sec disp-level="2"><title>smFRET imaging and data analysis</title><p>Labeled S&#x00394;TM spikes were immobilized on streptavidin-coated quartz microscope slides by way of Ni-NTA&#x02013;biotin (Sigma-Aldrich, St. Louis, MO, USA) and imaged using wide-field prism-based total internal reflection fluorescence microscopy as described (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>, <xref rid="R60" ref-type="bibr"><italic toggle="yes">60</italic></xref>, <xref rid="R99" ref-type="bibr"><italic toggle="yes">99</italic></xref>, <xref rid="R100" ref-type="bibr"><italic toggle="yes">100</italic></xref>). Imaging was performed in PBS containing 1 mM trolox (Sigma-Aldrich, St. Louis, MO, USA), 1 mM cyclooctatetraene (Sigma-Aldrich, St. Louis, MO, USA), 1 mM 4-nitrobenzyl alcohol (Sigma-Aldrich, St. Louis, MO, USA), 2 mM protocatechuic acid (Sigma-Aldrich, St. Louis, MO, USA), and 8 nM protocatechuate 3,4-deoxygenase (Sigma-Aldrich, St. Louis, MO, USA) to stabilize fluorescence and remove molecular oxygen. When indicated, labeled S&#x00394;TM spikes were incubated with shACE2 as described (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>), 300 &#x003bc;M of the indicated glycans for 30 min or 0.6 &#x003bc;M of the indicated mAb for 60 min before imaging. Concentrations of shACE2, the indicated glycans, and mAbs were maintained during imaging. smFRET data were collected using Micromanager v2.0 (<xref rid="R101" ref-type="bibr"><italic toggle="yes">101</italic></xref>) at 25 frames/s. All smFRET data were processed and analyzed using the SPARTAN software package (<ext-link xlink:href="https://scottcblanchardlab.com/software" ext-link-type="uri">https://scottcblanchardlab.com/software</ext-link>) in MATLAB (The Mathworks, Natick, MA) (<xref rid="R102" ref-type="bibr"><italic toggle="yes">102</italic></xref>). smFRET traces were identified according to criteria previously described (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>, <xref rid="R60" ref-type="bibr"><italic toggle="yes">60</italic></xref>). Traces meeting those criteria were then verified manually. Traces from each of three technical replicates were then compiled into FRET histograms, and the mean probability per histogram bin &#x000b1; SE was calculated. Traces were idealized to a three-state HMM (two nonzero-FRET states and a zero-FRET state) using the maximum point likelihood algorithm (<xref rid="R103" ref-type="bibr"><italic toggle="yes">103</italic></xref>) implemented in SPARTAN. The three-state model was previously selected by comparing the Akaike information criterion across multiple different models with a range of state numbers and topologies (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). The idealizations were used to determine the occupancies (fraction of time until photobleaching) in each FRET state and construct Gaussian distributions, which were overlaid on the FRET histograms to visualize the results of the HMM analysis. The distributions in occupancies were used to construct violin plots in MATLAB as well as calculate mean occupancy and SEs, as displayed in <xref rid="F7" ref-type="fig">Fig. 7</xref>. Statistical significance measures were determined as indicated below.</p></sec><sec disp-level="2"><title>Structural analysis</title><p>Protein structures (Protein Data Bank accession codes 7C2L and 7QUR) were visualized and analyzed using PyMOL software version 2.0.7 (Schr&#x000f6;dinger Inc., New York, NY). The S ectodomain structures were aligned to residues 719 to 1035 in S2 with RMSD of 0.903 &#x000c5;.</p></sec><sec disp-level="2"><title>Statistical analysis</title><p>Datasets subjected to statistical analysis were first tested for normality using GraphPad Prism version 10.0.1 (GraphPad Software, Boston, MA, USA). This information was used to apply the appropriate indicated parametric one-way analysis of variance (ANOVA) or nonparametric Kruskal-Wallis statistical test. Statistical significance measures (<italic toggle="yes">P</italic> values) of FRET state occupancies were determined by one-way ANOVA in MATLAB (The MathWorks, Waltham, MA, USA). This analysis displays the full breadth of dynamic behavior across the total population of traces analyzed. The total number of traces analyzed was sufficient to ensure minimally 85% statistical power during comparison of occupancy data from unbound to ligand-bound S&#x00394;TM (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). <italic toggle="yes">P</italic> values &#x0003c;0.05 were considered to indicate statistical significance.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>We thank T. Morrison (UMass Chan Medical School) for providing the HEK-293T-hACE2 cell line; B. K. Chen (Icahn School of Medicine at Mount Sinai) for providing the plasmid encoding the HIV-1 molecular clone HIV-1 NL4-3 Gag-iGFP &#x00394;Env; P. Kwong (NIAID, NIH) for providing the molecular clones of mAb 17b heavy and light chains; and M. Nussenzweig (The Rockefeller University) for providing molecular clones of both hIgG1 and hIgKappa expression vectors. We also thank Y. Wang (MassBiologics, UMass Chan Medical School) for providing the antibodies MAb362IgA1, REGN10987, and REGN10933.</p><sec><p><bold>Funding:</bold> This work was supported by the UMass Chan Medical School COVID-19 Pandemic Relief Fund (J.B.M.) and the National Institutes of Health grants R01GM143773 and R01AI174645 (J.B.M.).</p></sec><sec><p><bold>Author contributions:</bold> Conceptualization: M.A.D.-S. and J.B.M. Methodology: M.A.D.-S. and J.B.M. Investigation: M.A.D.-S. and A.J. Formal analysis: M.A.D.-S., A.J., and J.B.M. Software: J.B.M. Data curation: M.A.D.-S., A.J., and J.B.M. Visualization: M.A.D.-S., A.J., and J.B.M. Validation: M.A.D.-S., A.J., and J.B.M. Supervision: M.A.D.-S., N.D.D., and J.B.M. Resources: N.D.D. and J.B.M. Project administration: M.A.D.-S. and J.B.M. Funding acquisition: J.B.M. Writing&#x02014;original draft: M.A.D.-S. and J.B.M. Writing&#x02014;review and editing: All authors.</p></sec><sec><p><bold>Competing interests:</bold> The authors declare that they have no competing interests.</p></sec><sec><p><bold>Data and materials availability:</bold> All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.</p></sec></ack><sec sec-type="supplementary-material"><title>Supplementary Materials</title><sec><title>This PDF file includes:</title><supplementary-material position="float" content-type="local-data"><caption><p>Figs. S1 to S5</p></caption><media xlink:href="sciadv.adk4920_sm.pdf"/></supplementary-material></sec></sec><ref-list><title>REFERENCES AND NOTES</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>X.-L.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>X.-G.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Hu</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>H.-R.</given-names>
<surname>Si</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Zhu</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>C.-L.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>H.-D.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Luo</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Guo</surname></string-name>, <string-name><given-names>R.-D.</given-names>
<surname>Jiang</surname></string-name>, <string-name><given-names>M.-Q.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>X.-R.</given-names>
<surname>Shen</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>X.-S.</given-names>
<surname>Zheng</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Zhao</surname></string-name>, <string-name><given-names>Q.-J.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Deng</surname></string-name>, <string-name><given-names>L.-L.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Yan</surname></string-name>, <string-name><given-names>F.-X.</given-names>
<surname>Zhan</surname></string-name>, <string-name><given-names>Y.-Y.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>G.-F.</given-names>
<surname>Xiao</surname></string-name>, <string-name><given-names>Z.-L.</given-names>
<surname>Shi</surname></string-name></person-group>, 
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature</source>
<volume>579</volume>, 
<fpage>270</fpage>&#x02013;<lpage>273</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32015507</pub-id>
</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Hoffmann</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Kleine-Weber</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Schroeder</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Kr&#x000fc;ger</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Herrler</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Erichsen</surname></string-name>, <string-name><given-names>T. S.</given-names>
<surname>Schiergens</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Herrler</surname></string-name>, <string-name><given-names>N.-H.</given-names>
<surname>Wu</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Nitsche</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>M&#x000fc;ller</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Drosten</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>P&#x000f6;hlmann</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source>Cell</source>
<volume>181</volume>, 
<fpage>271</fpage>&#x02013;<lpage>280.e8</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32142651</pub-id>
</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Lan</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Ge</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Shan</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Fan</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Shi</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Wang</surname></string-name></person-group>, 
<article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title>. <source>Nature</source>
<volume>581</volume>, 
<fpage>215</fpage>&#x02013;<lpage>220</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32225176</pub-id>
</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Letko</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Marzi</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Munster</surname></string-name></person-group>, 
<article-title>Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses</article-title>. <source>Nat. Microbiol.</source>
<volume>5</volume>, 
<fpage>562</fpage>&#x02013;<lpage>569</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32094589</pub-id>
</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Shang</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Ye</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Shi</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Wan</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Luo</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Aihara</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Geng</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Auerbach</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Li</surname></string-name></person-group>, 
<article-title>Structural basis of receptor recognition by SARS-CoV-2</article-title>. <source>Nature</source>
<volume>581</volume>, 
<fpage>221</fpage>&#x02013;<lpage>224</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32225175</pub-id>
</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>Y.-J.</given-names>
<surname>Park</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Wall</surname></string-name>, <string-name><given-names>A. T.</given-names>
<surname>McGuire</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title>. <source>Cell</source>
<volume>181</volume>, 
<fpage>281</fpage>&#x02013;<lpage>292.e6</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32155444</pub-id>
</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Q.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Wu</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Niu</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Song</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Lu</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Qiao</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Hu</surname></string-name>, <string-name><given-names>K.-Y.</given-names>
<surname>Yuen</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Yan</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Qi</surname></string-name></person-group>, 
<article-title>Structural and functional basis of SARS-CoV-2 entry by using human ACE2</article-title>. <source>Cell</source>
<volume>181</volume>, 
<fpage>894</fpage>&#x02013;<lpage>904.e9</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32275855</pub-id>
</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Wrapp</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>K. S.</given-names>
<surname>Corbett</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Goldsmith</surname></string-name>, <string-name><given-names>C.-L.</given-names>
<surname>Hsieh</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Abiona</surname></string-name>, <string-name><given-names>B. S.</given-names>
<surname>Graham</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>McLellan</surname></string-name></person-group>, 
<article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title>. <source>Science</source>
<volume>367</volume>, 
<fpage>1260</fpage>&#x02013;<lpage>1263</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32075877</pub-id>
</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Yan</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Xia</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Guo</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Zhou</surname></string-name></person-group>, 
<article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title>. <source>Science</source>
<volume>367</volume>, 
<fpage>1444</fpage>&#x02013;<lpage>1448</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32132184</pub-id>
</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Tsybovsky</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Gorman</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Rapp</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Cerutti</surname></string-name>, <string-name><given-names>G.-Y.</given-names>
<surname>Chuang</surname></string-name>, <string-name><given-names>P. S.</given-names>
<surname>Katsamba</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Sampson</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Sch&#x000f6;n</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Bimela</surname></string-name>, <string-name><given-names>J. C.</given-names>
<surname>Boyington</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Nazzari</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Olia</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Shi</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Sastry</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Stephens</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Stuckey</surname></string-name>, <string-name><given-names>I.-T.</given-names>
<surname>Teng</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Friesner</surname></string-name>, <string-name><given-names>D. D.</given-names>
<surname>Ho</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Mascola</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Shapiro</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Kwong</surname></string-name></person-group>, 
<article-title>Cryo-EM structures of SARS-CoV-2 Spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains</article-title>. <source>Cell Host Microbe</source>
<volume>28</volume>, 
<fpage>867</fpage>&#x02013;<lpage>879.e5</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">33271067</pub-id>
</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Cai</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Xiao</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Peng</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Sterling</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>WalshJr</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Rawson</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Rits-Volloch</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Chen</surname></string-name></person-group>, 
<article-title>Distinct conformational states of SARS-CoV-2 spike protein</article-title>. <source>Science</source>
<volume>369</volume>, 
<fpage>1586</fpage>&#x02013;<lpage>1592</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32694201</pub-id>
</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Structural insights into coronavirus entry</article-title>. <source>Adv. Virus Res.</source>
<volume>105</volume>, 
<fpage>93</fpage>&#x02013;<lpage>116</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31522710</pub-id>
</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Snijder</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Xiong</surname></string-name>, <string-name><given-names>B.-J.</given-names>
<surname>Bosch</surname></string-name>, <string-name><given-names>F. A.</given-names>
<surname>Rey</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>114</volume>, 
<fpage>11157</fpage>&#x02013;<lpage>11162</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">29073020</pub-id>
</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Xiao</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Cai</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Chen</surname></string-name></person-group>, 
<article-title>Structure of SARS-CoV-2 spike protein</article-title>. <source>Curr. Opin. Virol.</source>
<volume>50</volume>, 
<fpage>173</fpage>&#x02013;<lpage>182</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34534731</pub-id>
</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>X.</given-names>
<surname>Chi</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Yan</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Hao</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Fan</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Dong</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Guo</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Song</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Xia</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Fu</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Hou</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Xu</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Chen</surname></string-name></person-group>, 
<article-title>A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2</article-title>. <source>Science</source>
<volume>369</volume>, 
<fpage>650</fpage>&#x02013;<lpage>655</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32571838</pub-id>
</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>McCallum</surname></string-name>, <string-name><given-names>A. D.</given-names>
<surname>Marco</surname></string-name>, <string-name><given-names>F. A.</given-names>
<surname>Lempp</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pinto</surname></string-name>, <string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Beltramello</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Zatta</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Zepeda</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>di Iulio</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Bowen</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Montiel-Ruiz</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>L. E.</given-names>
<surname>Rosen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bianchi</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Guarino</surname></string-name>, <string-name><given-names>C. S.</given-names>
<surname>Fregni</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Abdelnabi</surname></string-name>, <string-name><given-names>S.-Y. C.</given-names>
<surname>Foo</surname></string-name>, <string-name><given-names>P. W.</given-names>
<surname>Rothlauf</surname></string-name>, <string-name><given-names>L.-M.</given-names>
<surname>Bloyet</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Benigni</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Cameroni</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Neyts</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Riva</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Snell</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Telenti</surname></string-name>, <string-name><given-names>S. P. J.</given-names>
<surname>Whelan</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Virgin</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Pizzuto</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2</article-title>. <source>Cell</source>
<volume>184</volume>, 
<fpage>2332</fpage>&#x02013;<lpage>2347.e16</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33761326</pub-id>
</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names>
<surname>Cerutti</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Guo</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Gorman</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Rapp</surname></string-name>, <string-name><given-names>E. R.</given-names>
<surname>Reddem</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Bahna</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Bimela</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>P. S.</given-names>
<surname>Katsamba</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Nair</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Rawi</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Olia</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>G.-Y.</given-names>
<surname>Chuang</surname></string-name>, <string-name><given-names>D. D.</given-names>
<surname>Ho</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Sheng</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Kwong</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Shapiro</surname></string-name></person-group>, 
<article-title>Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite</article-title>. <source>Cell Host Microbe</source>
<volume>29</volume>, 
<fpage>819</fpage>&#x02013;<lpage>833.e7</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33789084</pub-id>
</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names>
<surname>Meng</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Datir</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Choi</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Bradley</surname></string-name>, <string-name><given-names>K. G. C.</given-names>
<surname>Smith</surname></string-name>, <string-name><given-names>J. H.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>R. K.</given-names>
<surname>Gupta</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Baker</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Dougan</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Hess</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Kingston</surname></string-name>, <string-name><given-names>P. J.</given-names>
<surname>Lehner</surname></string-name>, <string-name><given-names>P. A.</given-names>
<surname>Lyons</surname></string-name>, <string-name><given-names>N. J.</given-names>
<surname>Matheson</surname></string-name>, <string-name><given-names>W. H.</given-names>
<surname>Owehand</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Saunders</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Summers</surname></string-name>, <string-name><given-names>J. E. D.</given-names>
<surname>Thaventhiran</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Toshner</surname></string-name>, <string-name><given-names>M. P.</given-names>
<surname>Weekes</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Maxwell</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Shaw</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Bucke</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Calder</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Canna</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Domingo</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Elmer</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Fuller</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Harris</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Hewitt</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Kennet</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jose</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Kourampa</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Meadows</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>O&#x02019;Brien</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Price</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Publico</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Rastall</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Ribeiro</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Rowlands</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Ruffolo</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Tordesillas</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Bullman</surname></string-name>, <string-name><given-names>B. J.</given-names>
<surname>Dunmore</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Fawke</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Gr&#x000e4;f</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Hodgson</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Hunter</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Jones</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Legchenko</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Matara</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Martin</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Mescia</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>O&#x02019;Donnell</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Pointon</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Shih</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Sutcliffe</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Tilly</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Treacy</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Tong</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Wood</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Wylot</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Betancourt</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Bower</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Cossetti</surname></string-name>, <string-name><given-names>A. D.</given-names>
<surname>Sa</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Epping</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Fawke</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Gleadall</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Grenfell</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Hinch</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jackson</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Jarvis</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Krishna</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Nice</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Omarjee</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Perera</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Potts</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Richoz</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Romashova</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Stefanucci</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Strezlecki</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Turner</surname></string-name>, <string-name><given-names>E. M. D. D. D.</given-names>
<surname>Bie</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Bunclark</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Josipovic</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Mackay</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Allison</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Butcher</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Caputo</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Clapham-Riley</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Dewhurst</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Furlong</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Graves</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Gray</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Ivers</surname></string-name>, <string-name><given-names>E. L.</given-names>
<surname>Gresley</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Linger</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Meloy</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Muldoon</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Ovington</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Papadia</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Phelan</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Stark</surname></string-name>, <string-name><given-names>K. E.</given-names>
<surname>Stirrups</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Townsend</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Walker</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Webster</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Scholtes</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Hein</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>King</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity</article-title>. <source>Cell Rep.</source>
<volume>40</volume>, 
<fpage>111220</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35963244</pub-id>
</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names>
<surname>Qing</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Cooper</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Schulz</surname></string-name>, <string-name><given-names>H.-M.</given-names>
<surname>J&#x000e4;ck</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Rong</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Perlman</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Gallagher</surname></string-name></person-group>, 
<article-title>Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry</article-title>. <source>Cell Rep.</source>
<volume>39</volume>, 
<fpage>110786</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35477024</pub-id>
</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Otsubo</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Minamitani</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Kobiyama</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Fujita</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Ito</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Ueno</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Anzai</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Tanino</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Aoyama</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Matsuura</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Namba</surname></string-name>, <string-name><given-names>K.-I.</given-names>
<surname>Imadome</surname></string-name>, <string-name><given-names>K. J.</given-names>
<surname>Ishii</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Tsumoto</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Kamitani</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Yasui</surname></string-name></person-group>, 
<article-title>Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein</article-title>. <source>Sci. Rep.</source>
<volume>12</volume>, 
<fpage>20120</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">36418391</pub-id>
</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>Yurkovetskiy</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>K. E.</given-names>
<surname>Pascal</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Tomkins-Tinch</surname></string-name>, <string-name><given-names>T. P.</given-names>
<surname>Nyalile</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Baum</surname></string-name>, <string-name><given-names>W. E.</given-names>
<surname>Diehl</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Dauphin</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Carbone</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Veinotte</surname></string-name>, <string-name><given-names>S. B.</given-names>
<surname>Egri</surname></string-name>, <string-name><given-names>S. F.</given-names>
<surname>Schaffner</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Lemieux</surname></string-name>, <string-name><given-names>J. B.</given-names>
<surname>Munro</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Rafique</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Barve</surname></string-name>, <string-name><given-names>P. C.</given-names>
<surname>Sabeti</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Kyratsous</surname></string-name>, <string-name><given-names>N. V.</given-names>
<surname>Dudkina</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Shen</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Luban</surname></string-name></person-group>, 
<article-title>Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant</article-title>. <source>Cell</source>
<volume>183</volume>, 
<fpage>739</fpage>&#x02013;<lpage>751.e8</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32991842</pub-id>
</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Xu</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Hong</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Xu</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Zuo</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Cong</surname></string-name></person-group>, 
<article-title>Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM</article-title>. <source>Nat. Commun.</source>
<volume>12</volume>, 
<fpage>7345</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34930910</pub-id>
</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Cai</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Xiao</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Lu</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Peng</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Sterling</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>WalshJr</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Rits-Volloch</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Zhu</surname></string-name>, <string-name><given-names>A. N.</given-names>
<surname>Woosley</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Sliz</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Chen</surname></string-name></person-group>, 
<article-title>Structural impact on SARS-CoV-2 spike protein by D614G substitution</article-title>. <source>Science</source>
<volume>372</volume>, 
<fpage>525</fpage>&#x02013;<lpage>530</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33727252</pub-id>
</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Hong</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Xu</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Cong</surname></string-name></person-group>, 
<article-title>Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies</article-title>. <source>Nat. Commun.</source>
<volume>13</volume>, 
<fpage>871</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35169135</pub-id>
</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names>
<surname>Ye</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Li</surname></string-name></person-group>, 
<article-title>Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain</article-title>. <source>Nat. Commun.</source>
<volume>13</volume>, 
<fpage>1214</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35241675</pub-id>
</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Lu</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Uchil</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Zheng</surname></string-name>, <string-name><given-names>D. S.</given-names>
<surname>Terry</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Gorman</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Shi</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Ding</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Gasser</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Pr&#x000e9;vost</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Beaudoin-Bussi&#x000e8;res</surname></string-name>, <string-name><given-names>S. P.</given-names>
<surname>Anand</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Laumaea</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Grover</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>D. D.</given-names>
<surname>Ho</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Mascola</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Finzi</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Kwong</surname></string-name>, <string-name><given-names>S. C.</given-names>
<surname>Blanchard</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Mothes</surname></string-name></person-group>, 
<article-title>Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles</article-title>. <source>Cell Host Microbe</source>
<volume>28</volume>, 
<fpage>880</fpage>&#x02013;<lpage>891.e8</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">33242391</pub-id>
</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Z.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Han</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Ding</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Shi</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Finzi</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Kwong</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Mothes</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Lu</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 variants increase kinetic stability of open spike conformations as an evolutionary strategy</article-title>. <source>MBio</source>
<volume>13</volume>, 
<fpage>e03227</fpage>&#x02013;<lpage>e03221</lpage> (<year>2022</year>).</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. A.</given-names>
<surname>D&#x000ed;az-Salinas</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Ejemel</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Yurkovetskiy</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Luban</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Shen</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>J. B.</given-names>
<surname>Munro</surname></string-name></person-group>, 
<article-title>Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike</article-title>. <source>eLife</source>
<volume>11</volume>, 
<fpage>e75433</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35323111</pub-id>
</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. Y.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Jin</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Sood</surname></string-name>, <string-name><given-names>D. W.</given-names>
<surname>Montgomery</surname></string-name>, <string-name><given-names>O. C.</given-names>
<surname>Grant</surname></string-name>, <string-name><given-names>M. M.</given-names>
<surname>Fuster</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Fu</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Dordick</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Woods</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Linhardt</surname></string-name></person-group>, 
<article-title>Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions</article-title>. <source>Antiviral Res.</source>
<volume>181</volume>, 
<fpage>104873</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32653452</pub-id>
</mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>S. J. L.</given-names>
<surname>Petitjean</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Koehler</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>A. C.</given-names>
<surname>Dumitru</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Derclaye</surname></string-name>, <string-name><given-names>S. P.</given-names>
<surname>Vincent</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Soumillion</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Alsteens</surname></string-name></person-group>, 
<article-title>Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor</article-title>. <source>Nat. Commun.</source>
<volume>11</volume>, 
<fpage>4541</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32917884</pub-id>
</mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T. M.</given-names>
<surname>Clausen</surname></string-name>, <string-name><given-names>D. R.</given-names>
<surname>Sandoval</surname></string-name>, <string-name><given-names>C. B.</given-names>
<surname>Spliid</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Pihl</surname></string-name>, <string-name><given-names>H. R.</given-names>
<surname>Perrett</surname></string-name>, <string-name><given-names>C. D.</given-names>
<surname>Painter</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Narayanan</surname></string-name>, <string-name><given-names>S. A.</given-names>
<surname>Majowicz</surname></string-name>, <string-name><given-names>E. M.</given-names>
<surname>Kwong</surname></string-name>, <string-name><given-names>R. N.</given-names>
<surname>McVicar</surname></string-name>, <string-name><given-names>B. E.</given-names>
<surname>Thacker</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Glass</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>J. L.</given-names>
<surname>Torres</surname></string-name>, <string-name><given-names>G. J.</given-names>
<surname>Golden</surname></string-name>, <string-name><given-names>P. L.</given-names>
<surname>Bartels</surname></string-name>, <string-name><given-names>R. N.</given-names>
<surname>Porell</surname></string-name>, <string-name><given-names>A. F.</given-names>
<surname>Garretson</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Laubach</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Feldman</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Yin</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Pu</surname></string-name>, <string-name><given-names>B. M.</given-names>
<surname>Hauser</surname></string-name>, <string-name><given-names>T. M.</given-names>
<surname>Caradonna</surname></string-name>, <string-name><given-names>B. P.</given-names>
<surname>Kellman</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Martino</surname></string-name>, <string-name><given-names>P. L. S. M.</given-names>
<surname>Gordts</surname></string-name>, <string-name><given-names>S. K.</given-names>
<surname>Chanda</surname></string-name>, <string-name><given-names>A. G.</given-names>
<surname>Schmidt</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Godula</surname></string-name>, <string-name><given-names>S. L.</given-names>
<surname>Leibel</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Jose</surname></string-name>, <string-name><given-names>K. D.</given-names>
<surname>Corbett</surname></string-name>, <string-name><given-names>A. B.</given-names>
<surname>Ward</surname></string-name>, <string-name><given-names>A. F.</given-names>
<surname>Carlin</surname></string-name>, <string-name><given-names>J. D.</given-names>
<surname>Esko</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2</article-title>. <source>Cell</source>
<volume>183</volume>, 
<fpage>1043</fpage>&#x02013;<lpage>1057.e15</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32970989</pub-id>
</mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W.</given-names>
<surname>Hao</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Ma</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Gao</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Qin</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Shang</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Cui</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Tan</surname></string-name></person-group>, 
<article-title>Binding of the SARS-CoV-2 spike protein to glycans</article-title>. <source>Sci. Bull.</source>
<volume>66</volume>, 
<fpage>1205</fpage>&#x02013;<lpage>1214</lpage> (<year>2021</year>).</mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Chopra</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>K. M.</given-names>
<surname>Bouwman</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Tompkins</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Wolfert</surname></string-name>, <string-name><given-names>R. P.</given-names>
<surname>de Vries</surname></string-name>, <string-name><given-names>G.-J.</given-names>
<surname>Boons</surname></string-name></person-group>, 
<article-title>Heparan sulfate proteoglycans as attachment factor for SARS-CoV-2</article-title>. <source>ACS Cent. Sci.</source>
<volume>7</volume>, 
<fpage>1009</fpage>&#x02013;<lpage>1018</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34235261</pub-id>
</mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.-C.</given-names>
<surname>Wu</surname></string-name>, <string-name><given-names>C. M.</given-names>
<surname>Arthur</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Verkerke</surname></string-name>, <string-name><given-names>C. D.</given-names>
<surname>Josephson</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Kalman</surname></string-name>, <string-name><given-names>J. D.</given-names>
<surname>Roback</surname></string-name>, <string-name><given-names>R. D.</given-names>
<surname>Cummings</surname></string-name>, <string-name><given-names>S. R.</given-names>
<surname>Stowell</surname></string-name></person-group>, 
<article-title>The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A</article-title>. <source>Blood Adv.</source>
<volume>5</volume>, 
<fpage>1305</fpage>&#x02013;<lpage>1309</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33656534</pub-id>
</mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>Nguyen</surname></string-name>, <string-name><given-names>K. A.</given-names>
<surname>McCord</surname></string-name>, <string-name><given-names>D. T.</given-names>
<surname>Bui</surname></string-name>, <string-name><given-names>K. M.</given-names>
<surname>Bouwman</surname></string-name>, <string-name><given-names>E. N.</given-names>
<surname>Kitova</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Elaish</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Kumawat</surname></string-name>, <string-name><given-names>G. C.</given-names>
<surname>Daskhan</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Tomris</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Han</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Chopra</surname></string-name>, <string-name><given-names>T.-J.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>S. D.</given-names>
<surname>Willows</surname></string-name>, <string-name><given-names>A. L.</given-names>
<surname>Mason</surname></string-name>, <string-name><given-names>L. K.</given-names>
<surname>Mahal</surname></string-name>, <string-name><given-names>T. L.</given-names>
<surname>Lowary</surname></string-name>, <string-name><given-names>L. J.</given-names>
<surname>West</surname></string-name>, <string-name><given-names>S.-T. D.</given-names>
<surname>Hsu</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Hobman</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Tompkins</surname></string-name>, <string-name><given-names>G.-J.</given-names>
<surname>Boons</surname></string-name>, <string-name><given-names>R. P.</given-names>
<surname>de Vries</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Macauley</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Klassen</surname></string-name></person-group>, 
<article-title>Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2</article-title>. <source>Nat. Chem. Biol.</source>
<volume>18</volume>, 
<fpage>81</fpage>&#x02013;<lpage>90</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">34754101</pub-id>
</mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>Unione</surname></string-name>, <string-name><given-names>M. J.</given-names>
<surname>Moure</surname></string-name>, <string-name><given-names>M. P.</given-names>
<surname>Lenza</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Oyenarte</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Ere&#x000f1;o-Orbea</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Ard&#x000e1;</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Jim&#x000e9;nez-Barbero</surname></string-name></person-group>, 
<article-title>The SARS-CoV-2 spike glycoprotein directly binds exogeneous sialic acids: A NMR view</article-title>. <source>Angew. Chem. Int. Ed.</source>
<volume>61</volume>, 
<fpage>e202201432</fpage> (<year>2022</year>).</mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Creutznacher</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Maass</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Veselkova</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Ssebyatika</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Krey</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Empting</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Tautz</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Frank</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>K&#x000f6;lbel</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Uetrecht</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Peters</surname></string-name></person-group>, 
<article-title>NMR Experiments provide insights into ligand-binding to the SARS-CoV-2 spike protein receptor-binding domain</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>144</volume>, 
<fpage>13060</fpage>&#x02013;<lpage>13065</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35830336</pub-id>
</mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Maass</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Ssebyatika</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Br&#x000fc;ckner</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Breckwoldt</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Krey</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Mallagaray</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Peters</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Frank</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Creutznacher</surname></string-name></person-group>, 
<article-title>Binding of glycans to the SARS CoV-2 spike protein, an open question: NMR data on binding site localization, affinity, and selectivity</article-title>. <source>Chem. A Eur. J.</source>
<volume>28</volume>, 
<fpage>e202202614</fpage> (<year>2022</year>).</mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Fantini</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Chahinian</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Yahi</surname></string-name></person-group>, 
<article-title>Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal</article-title>. <source>Int. J. Antimicrob. Agents</source>
<volume>56</volume>, 
<fpage>106020</fpage> (<year>2020</year>).</mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Fantini</surname></string-name>, <string-name><given-names>C. D.</given-names>
<surname>Scala</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Chahinian</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Yahi</surname></string-name></person-group>, 
<article-title>Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection</article-title>. <source>Int. J. Antimicrob. Agents</source>
<volume>55</volume>, 
<fpage>105960</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32251731</pub-id>
</mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Awasthi</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Gulati</surname></string-name>, <string-name><given-names>D. P.</given-names>
<surname>Sarkar</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Tiwari</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kateriya</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Ranjan</surname></string-name>, <string-name><given-names>S. K.</given-names>
<surname>Verma</surname></string-name></person-group>, 
<article-title>The sialoside-binding pocket of SARS-CoV-2 spike glycoprotein structurally resembles MERS-CoV</article-title>. <source>Viruses</source>
<volume>12</volume>, 
<fpage>909</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32825063</pub-id>
</mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>B&#x000f2;</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Miotto</surname></string-name>, <string-name><given-names>L. D.</given-names>
<surname>Rienzo</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Milanetti</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Ruocco</surname></string-name></person-group>, 
<article-title>Exploring the association between sialic acid and SARS-CoV-2 spike protein through a molecular dynamics-based approach</article-title>. <source>Front. M&#x000e9;d. Technol.</source>
<volume>2</volume>, 
<fpage>614652</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">35047894</pub-id>
</mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. J.</given-names>
<surname>Buchanan</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Gaunt</surname></string-name>, <string-name><given-names>P. J.</given-names>
<surname>Harrison</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Khan</surname></string-name>, <string-name><given-names>A. M.</given-names>
<surname>Giltrap</surname></string-name>, <string-name><given-names>A. L.</given-names>
<surname>Bas</surname></string-name>, <string-name><given-names>P. N.</given-names>
<surname>Ward</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Gupta</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Dumoux</surname></string-name>, <string-name><given-names>T. K.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Schimaski</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Daga</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Picchiotti</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Baldassarri</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Benetti</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Fallerini</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Fava</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Giliberti</surname></string-name>, <string-name><given-names>P. I.</given-names>
<surname>Koukos</surname></string-name>, <string-name><given-names>M. J.</given-names>
<surname>Davy</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lakshminarayanan</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Xue</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Papadakis</surname></string-name>, <string-name><given-names>L. P.</given-names>
<surname>Deimel</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Casablancas-Antr&#x000e0;s</surname></string-name>, <string-name><given-names>T. D. W.</given-names>
<surname>Claridge</surname></string-name>, <string-name><given-names>A. M. J. J.</given-names>
<surname>Bonvin</surname></string-name>, <string-name><given-names>Q. J.</given-names>
<surname>Sattentau</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Furini</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Gori</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Huo</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Owens</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Schaffitzel</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Berger</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Renieri</surname></string-name>, <string-name><given-names>G.-C. M.</given-names>
<surname>Study</surname></string-name>, <string-name><given-names>J. H.</given-names>
<surname>Naismith</surname></string-name>, <string-name><given-names>A. J.</given-names>
<surname>Baldwin</surname></string-name>, <string-name><given-names>B. G.</given-names>
<surname>Davis</surname></string-name></person-group>, 
<article-title>Pathogen-sugar interactions revealed by universal saturation transfer analysis</article-title>. <source>Science</source>
<volume>377</volume>, 
<fpage>eabm3125</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35737812</pub-id>
</mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names>
<surname>Guo</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>H.-F.</given-names>
<surname>Lin</surname></string-name>, <string-name><given-names>M.-Q.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>T.-T.</given-names>
<surname>Jiang</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>M. C.</given-names>
<surname>Letko</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Peng</surname></string-name>, <string-name><given-names>Z.-L.</given-names>
<surname>Shi</surname></string-name></person-group>, 
<article-title>The glycan-binding trait of the sarbecovirus spike N-terminal domain reveals an evolutionary footprint</article-title>. <source>J. Virol.</source>
<volume>96</volume>, 
<fpage>e0095822</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35852351</pub-id>
</mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>I.</given-names>
<surname>Tomris</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Unione</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Nguyen</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Zaree</surname></string-name>, <string-name><given-names>K. M.</given-names>
<surname>Bouwman</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Fok</surname></string-name>, <string-name><given-names>M. R.</given-names>
<surname>Carrasco</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>van der Woude</surname></string-name>, <string-name><given-names>A. L. M.</given-names>
<surname>Kimpel</surname></string-name>, <string-name><given-names>M. W.</given-names>
<surname>Linthorst</surname></string-name>, <string-name><given-names>S. E.</given-names>
<surname>Kilavuzoglu</surname></string-name>, <string-name><given-names>E. C. J. M.</given-names>
<surname>Verpalen</surname></string-name>, <string-name><given-names>T. G.</given-names>
<surname>Caniels</surname></string-name>, <string-name><given-names>R. W.</given-names>
<surname>Sanders</surname></string-name>, <string-name><given-names>B. A.</given-names>
<surname>Heesters</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Pieters</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Jim&#x000e9;nez-Barbero</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Klassen</surname></string-name>, <string-name><given-names>G.-J.</given-names>
<surname>Boons</surname></string-name>, <string-name><given-names>R. P.</given-names>
<surname>de Vries</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 spike N-terminal domain engages 9-O-acetylated &#x003b1;2&#x02013;8-linked sialic acids</article-title>. <source>ACS Chem. Biol.</source>
<volume>18</volume>, 
<fpage>1180</fpage>&#x02013;<lpage>1191</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37104622</pub-id>
</mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. J. L.</given-names>
<surname>Petitjean</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Koehler</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Jimmidi</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Mohammed</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Juniku</surname></string-name>, <string-name><given-names>M. L.</given-names>
<surname>Stanifer</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Boulant</surname></string-name>, <string-name><given-names>S. P.</given-names>
<surname>Vincent</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Alsteens</surname></string-name></person-group>, 
<article-title>Multivalent 9-O-acetylated-sialic acid glycoclusters as potent inhibitors for SARS-CoV-2 infection</article-title>. <source>Nat. Commun.</source>
<volume>13</volume>, 
<fpage>2564</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35538121</pub-id>
</mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W.</given-names>
<surname>Saso</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Yamasaki</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Nakakita</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Fukushi</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Tsuchimoto</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Watanabe</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Sriwilaijaroen</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Kanie</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Muramatsu</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Takahashi</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Matano</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Takeda</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Suzuki</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Watashi</surname></string-name></person-group>, 
<article-title>Significant role of host sialylated glycans in the infection and spread of severe acute respiratory syndrome coronavirus 2</article-title>. <source>PLOS Pathog.</source>
<volume>18</volume>, 
<fpage>e1010590</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35700214</pub-id>
</mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. N.</given-names>
<surname>Neerukonda</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Vassell</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Herrup</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Takeda</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>T.-L.</given-names>
<surname>Lin</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>C. D.</given-names>
<surname>Weiss</surname></string-name></person-group>, 
<article-title>Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2</article-title>. <source>PLOS ONE</source>
<volume>16</volume>, 
<fpage>e0248348</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33690649</pub-id>
</mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. N.</given-names>
<surname>Neerukonda</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Vassell</surname></string-name>, <string-name><given-names>C. D.</given-names>
<surname>Weiss</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Wang</surname></string-name></person-group>, 
<article-title>Measuring neutralizing antibodies to SARS-CoV-2 using lentiviral spike-pseudoviruses</article-title>. <source>Methods Mol. Biol.</source>
<volume>2452</volume>, 
<fpage>305</fpage>&#x02013;<lpage>314</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35554914</pub-id>
</mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>V.</given-names>
<surname>Monteil</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Kwon</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Prado</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Hagelkr&#x000fc;ys</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Wimmer</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Stahl</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Leopoldi</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Garreta</surname></string-name>, <string-name><given-names>C. H.</given-names>
<surname>del Pozo</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Prosper</surname></string-name>, <string-name><given-names>J. P.</given-names>
<surname>Romero</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Wirnsberger</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Slutsky</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Conder</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Montserrat</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Mirazimi</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Penninger</surname></string-name></person-group>, 
<article-title>Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2</article-title>. <source>Cell</source>
<volume>181</volume>, 
<fpage>905</fpage>&#x02013;<lpage>913.e7</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32333836</pub-id>
</mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. K.</given-names>
<surname>Chan</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Dorosky</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Sharma</surname></string-name>, <string-name><given-names>S. A.</given-names>
<surname>Abbasi</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Dye</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Kranz</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Herbert</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Procko</surname></string-name></person-group>, 
<article-title>Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2</article-title>. <source>Science</source>
<volume>369</volume>, 
<fpage>1261</fpage>&#x02013;<lpage>1265</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32753553</pub-id>
</mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names>
<surname>Miyauchi</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Latinovic</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Morozov</surname></string-name>, <string-name><given-names>G. B.</given-names>
<surname>Melikyan</surname></string-name></person-group>, 
<article-title>HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes</article-title>. <source>Cell</source>
<volume>137</volume>, 
<fpage>433</fpage>&#x02013;<lpage>444</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19410541</pub-id>
</mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.-M.</given-names>
<surname>Lip</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Shen</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>C.-T.</given-names>
<surname>Keng</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>H.-L. J.</given-names>
<surname>Oh</surname></string-name>, <string-name><given-names>Z.-H.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>L.-A.</given-names>
<surname>Hwang</surname></string-name>, <string-name><given-names>C.-F.</given-names>
<surname>Chou</surname></string-name>, <string-name><given-names>B. C.</given-names>
<surname>Fielding</surname></string-name>, <string-name><given-names>T. H. P.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Mayrhofer</surname></string-name>, <string-name><given-names>F. G.</given-names>
<surname>Falkner</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Fu</surname></string-name>, <string-name><given-names>S. G.</given-names>
<surname>Lim</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Hong</surname></string-name>, <string-name><given-names>Y.-J.</given-names>
<surname>Tan</surname></string-name></person-group>, 
<article-title>Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the s protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus</article-title>. <source>J. Virol.</source>
<volume>80</volume>, 
<fpage>941</fpage>&#x02013;<lpage>950</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16378996</pub-id>
</mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names>
<surname>Chu</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Hu</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Chai</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Shuai</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Hou</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>T. T.-T.</given-names>
<surname>Yuen</surname></string-name>, <string-name><given-names>J.-P.</given-names>
<surname>Cai</surname></string-name>, <string-name><given-names>A. J.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Yuan</surname></string-name>, <collab id="coll01">K. K.-W. To</collab>, <string-name><given-names>I. H.-Y.</given-names>
<surname>Chan</surname></string-name>, <string-name><given-names>K.-Y.</given-names>
<surname>Sit</surname></string-name>, <string-name><given-names>D. C.-C.</given-names>
<surname>Foo</surname></string-name>, <string-name><given-names>I. Y.-H.</given-names>
<surname>Wong</surname></string-name>, <string-name><given-names>A. T.-L.</given-names>
<surname>Ng</surname></string-name>, <string-name><given-names>T. T.</given-names>
<surname>Cheung</surname></string-name>, <string-name><given-names>S. Y.-K.</given-names>
<surname>Law</surname></string-name>, <string-name><given-names>W.-K.</given-names>
<surname>Au</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Brindley</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>K.-H.</given-names>
<surname>Kok</surname></string-name>, <string-name><given-names>J. F.-W.</given-names>
<surname>Chan</surname></string-name>, <string-name><given-names>K.-Y.</given-names>
<surname>Yuen</surname></string-name></person-group>, 
<article-title>Host and viral determinants for efficient SARS-CoV-2 infection of the human lung</article-title>. <source>Nat. Commun.</source>
<volume>12</volume>, 
<fpage>134</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33420022</pub-id>
</mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Q.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>T. A.</given-names>
<surname>Hughes</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Kelkar</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Cheng</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Park</surname></string-name>, <string-name><given-names>W.-C.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>J. F.</given-names>
<surname>Lovell</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Neelamegham</surname></string-name></person-group>, 
<article-title>Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration</article-title>. <source>eLife</source>
<volume>9</volume>, 
<fpage>e61552</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">33103998</pub-id>
</mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. J.</given-names>
<surname>Linman</surname></string-name>, <string-name><given-names>J. D.</given-names>
<surname>Taylor</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Cheng</surname></string-name></person-group>, 
<article-title>Surface plasmon resonance study of protein&#x02212;Carbohydrate interactions using biotinylated sialosides</article-title>. <source>Anal. Chem.</source>
<volume>80</volume>, 
<fpage>4007</fpage>&#x02013;<lpage>4013</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18461973</pub-id>
</mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W. B.</given-names>
<surname>Williams</surname></string-name>, <string-name><given-names>R. R.</given-names>
<surname>Meyerhoff</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Edwards</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Manne</surname></string-name>, <string-name><given-names>N. I.</given-names>
<surname>Nicely</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Henderson</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Janowska</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Mansouri</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Gobeil</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Evangelous</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Hora</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Berry</surname></string-name>, <string-name><given-names>A. Y.</given-names>
<surname>Abuahmad</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Sprenz</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Deyton</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Stalls</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Kopp</surname></string-name>, <string-name><given-names>A. L.</given-names>
<surname>Hsu</surname></string-name>, <string-name><given-names>M. J.</given-names>
<surname>Borgnia</surname></string-name>, <string-name><given-names>G. B. E.</given-names>
<surname>Stewart-Jones</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Bronkema</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Moody</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Wiehe</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Bradley</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Alam</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Parks</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Foulger</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Oguin</surname></string-name>, <string-name><given-names>G. D.</given-names>
<surname>Sempowski</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Bonsignori</surname></string-name>, <string-name><given-names>C. C.</given-names>
<surname>LaBranche</surname></string-name>, <string-name><given-names>D. C.</given-names>
<surname>Montefiori</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Seaman</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Santra</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Perfect</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Francica</surname></string-name>, <string-name><given-names>G. M.</given-names>
<surname>Lynn</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Aussedat</surname></string-name>, <string-name><given-names>W. E.</given-names>
<surname>Walkowicz</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Laga</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Kelsoe</surname></string-name>, <string-name><given-names>K. O.</given-names>
<surname>Saunders</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Fera</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Kwong</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Seder</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Bartesaghi</surname></string-name>, <string-name><given-names>G. M.</given-names>
<surname>Shaw</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Acharya</surname></string-name>, <string-name><given-names>B. F.</given-names>
<surname>Haynes</surname></string-name></person-group>, 
<article-title>Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies</article-title>. <source>Cell</source>
<volume>184</volume>, 
<fpage>2955</fpage>&#x02013;<lpage>2972.e25</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34019795</pub-id>
</mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Ejemel</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Hou</surname></string-name>, <string-name><given-names>Z. A.</given-names>
<surname>Schiller</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Tree</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Wallace</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Amcheslavsky</surname></string-name>, <string-name><given-names>N. K.</given-names>
<surname>Yilmaz</surname></string-name>, <string-name><given-names>K. R.</given-names>
<surname>Buttigieg</surname></string-name>, <string-name><given-names>M. J.</given-names>
<surname>Elmore</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Godwin</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Coombes</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Toomey</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Schneider</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Ramchetty</surname></string-name>, <string-name><given-names>B. J.</given-names>
<surname>Close</surname></string-name>, <string-name><given-names>D.-Y.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>H. L.</given-names>
<surname>Conway</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Saeed</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Ganesa</surname></string-name>, <string-name><given-names>M. W.</given-names>
<surname>Carroll</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>Cavacini</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Klempner</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Schiffer</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Wang</surname></string-name></person-group>, 
<article-title>A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction</article-title>. <source>Nat. Commun.</source>
<volume>11</volume>, 
<fpage>4198</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32826914</pub-id>
</mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Hansen</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Baum</surname></string-name>, <string-name><given-names>K. E.</given-names>
<surname>Pascal</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Russo</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Giordano</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Wloga</surname></string-name>, <string-name><given-names>B. O.</given-names>
<surname>Fulton</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Yan</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Koon</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Patel</surname></string-name>, <string-name><given-names>K. M.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Hermann</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Ullman</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Cruz</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Rafique</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Fairhurst</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Libertiny</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Malbec</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Welsh</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Farr</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Pennington</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Deshpande</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Cheng</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Watty</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Bouffard</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Babb</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Levenkova</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>A. R.</given-names>
<surname>Hernandez</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Saotome</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Franklin</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Sivapalasingam</surname></string-name>, <string-name><given-names>D. C.</given-names>
<surname>Lye</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Weston</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Logue</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Haupt</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Frieman</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Olson</surname></string-name>, <string-name><given-names>A. J.</given-names>
<surname>Murphy</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Stahl</surname></string-name>, <string-name><given-names>G. D.</given-names>
<surname>Yancopoulos</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Kyratsous</surname></string-name></person-group>, 
<article-title>Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail</article-title>. <source>Science</source>
<volume>369</volume>, 
<fpage>1010</fpage>&#x02013;<lpage>1014</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32540901</pub-id>
</mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. B.</given-names>
<surname>Egri</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>D&#x000ed;az-Salinas</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Luban</surname></string-name>, <string-name><given-names>N. V.</given-names>
<surname>Dudkina</surname></string-name>, <string-name><given-names>J. B.</given-names>
<surname>Munro</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Shen</surname></string-name></person-group>, 
<article-title>Detergent modulates the conformational equilibrium of SARS-CoV-2 Spike during cryo-EM structural determination</article-title>. <source>Nat. Commun.</source>
<volume>14</volume>, 
<fpage>2527</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37137903</pub-id>
</mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Matrosovich</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Herrler</surname></string-name>, <string-name><given-names>H. D.</given-names>
<surname>Klenk</surname></string-name></person-group>, 
<article-title>SialoGlyco chemistry and biology II, tools and techniques to identify and capture sialoglycans</article-title>. <source>SialoGlyco Chem. Biol.</source>
<volume>367</volume>, 
<fpage>1</fpage>&#x02013;<lpage>28</lpage> (<year>2013</year>).</mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Koehler</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Delguste</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Sieben</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Gillet</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Alsteens</surname></string-name></person-group>, 
<article-title>Initial step of virus entry: Virion binding to cell-surface glycans</article-title>. <source>Annu. Rev. Virol.</source>
<volume>7</volume>, 
<fpage>143</fpage>&#x02013;<lpage>165</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32396772</pub-id>
</mixed-citation></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Marsh</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Helenius</surname></string-name></person-group>, 
<article-title>Virus entry: Open sesame</article-title>. <source>Cell</source>
<volume>124</volume>, 
<fpage>729</fpage>&#x02013;<lpage>740</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16497584</pub-id>
</mixed-citation></ref><ref id="R64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Wallert</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Nie</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Anilkumar</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Abbina</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bhatia</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Ludwig</surname></string-name>, <string-name><given-names>J. N.</given-names>
<surname>Kizhakkedathu</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Haag</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Block</surname></string-name></person-group>, 
<article-title>Mucin-inspired, high molecular weight virus binding inhibitors show biphasic binding behavior to influenza A viruses</article-title>. <source>Small</source>
<volume>16</volume>, 
<fpage>e2004635</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">33135314</pub-id>
</mixed-citation></ref><ref id="R65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. D.</given-names>
<surname>Esko</surname></string-name>, <string-name><given-names>S. B.</given-names>
<surname>Selleck</surname></string-name></person-group>, 
<article-title>ORDER OUT OF CHAOS: Assembly of ligand binding sites in heparan sulfate</article-title>. <source>Annu. Rev. Biochem.</source>
<volume>71</volume>, 
<fpage>435</fpage>&#x02013;<lpage>471</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12045103</pub-id>
</mixed-citation></ref><ref id="R66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. F.</given-names>
<surname>Pronker</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Creutznacher</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Drulyte</surname></string-name>, <string-name><given-names>R. J. G.</given-names>
<surname>Hulswit</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>F. J. M.</given-names>
<surname>van Kuppeveld</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Snijder</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Lang</surname></string-name>, <string-name><given-names>B.-J.</given-names>
<surname>Bosch</surname></string-name>, <string-name><given-names>G.-J.</given-names>
<surname>Boons</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Frank</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>de Groot</surname></string-name>, <string-name><given-names>D. L.</given-names>
<surname>Hurdiss</surname></string-name></person-group>, 
<article-title>Sialoglycan binding triggers spike opening in a human coronavirus</article-title>. <source>Nature</source>
<volume>624</volume>, 
<fpage>201</fpage>&#x02013;<lpage>206</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37794193</pub-id>
</mixed-citation></ref><ref id="R67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. K.</given-names>
<surname>Das</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Govindan</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Niki&#x00107;-Spiegel</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Krammer</surname></string-name>, <string-name><given-names>E. A.</given-names>
<surname>Lemke</surname></string-name>, <string-name><given-names>J. B.</given-names>
<surname>Munro</surname></string-name></person-group>, 
<article-title>Direct visualization of the conformational dynamics of single influenza hemagglutinin trimers</article-title>. <source>Cell</source>
<volume>174</volume>, 
<fpage>926</fpage>&#x02013;<lpage>937.e12</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29961575</pub-id>
</mixed-citation></ref><ref id="R68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P. V.</given-names>
<surname>Raghuvamsi</surname></string-name>, <string-name><given-names>N. K.</given-names>
<surname>Tulsian</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Samsudin</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Qian</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Purushotorman</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Yue</surname></string-name>, <string-name><given-names>M. M.</given-names>
<surname>Kozma</surname></string-name>, <string-name><given-names>W. Y.</given-names>
<surname>Hwa</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Lescar</surname></string-name>, <string-name><given-names>P. J.</given-names>
<surname>Bond</surname></string-name>, <string-name><given-names>P. A.</given-names>
<surname>MacAry</surname></string-name>, <string-name><given-names>G. S.</given-names>
<surname>Anand</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targets</article-title>. <source>eLife</source>
<volume>10</volume>, 
<fpage>e63646</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33554856</pub-id>
</mixed-citation></ref><ref id="R69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Zheng</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Deng</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Wong</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Lavillette</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Meng</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 spike engagement of ACE2 primes S2&#x02032; site cleavage and fusion initiation</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>119</volume>, 
<fpage>e2111199119</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">34930824</pub-id>
</mixed-citation></ref><ref id="R70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Xiang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Su</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Lan</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Zhao</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Xu</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Niu</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Xia</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Qi</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Sidhu</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Lu</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Miersch</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Yang</surname></string-name></person-group>, 
<article-title>Antigenic mapping reveals sites of vulnerability on &#x003b1;-HCoV spike protein</article-title>. <source>Commun. Biol.</source>
<volume>5</volume>, 
<fpage>1179</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">36333470</pub-id>
</mixed-citation></ref><ref id="R71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>E. L.</given-names>
<surname>Hesketh</surname></string-name>, <string-name><given-names>T. M.</given-names>
<surname>Shamorkina</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>P. J.</given-names>
<surname>Franken</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Drabek</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>van Haperen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Townend</surname></string-name>, <string-name><given-names>F. J. M.</given-names>
<surname>van Kuppeveld</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Grosveld</surname></string-name>, <string-name><given-names>N. A.</given-names>
<surname>Ranson</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Snijder</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>de Groot</surname></string-name>, <string-name><given-names>D. L.</given-names>
<surname>Hurdiss</surname></string-name>, <string-name><given-names>B.-J.</given-names>
<surname>Bosch</surname></string-name></person-group>, 
<article-title>Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes</article-title>. <source>Nat. Commun.</source>
<volume>13</volume>, 
<fpage>2921</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35614127</pub-id>
</mixed-citation></ref><ref id="R72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. D.</given-names>
<surname>Lam</surname></string-name>, <string-name><given-names>V. P.</given-names>
<surname>Waman</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Fraternali</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Orengo</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Lees</surname></string-name></person-group>, 
<article-title>Structural and energetic analyses of SARS-CoV-2 N-terminal domain characterise sugar binding pockets and suggest putative impacts of variants on COVID-19 transmission</article-title>. <source>Comput. Struct. Biotechnol. J.</source>
<volume>20</volume>, 
<fpage>6302</fpage>&#x02013;<lpage>6316</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">36408455</pub-id>
</mixed-citation></ref><ref id="R73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>E. S.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Schramm</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Shi</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Pegu</surname></string-name>, <string-name><given-names>O. K.</given-names>
<surname>Oloniniyi</surname></string-name>, <string-name><given-names>A. R.</given-names>
<surname>Henry</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Darko</surname></string-name>, <string-name><given-names>S. R.</given-names>
<surname>Narpala</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Hatcher</surname></string-name>, <string-name><given-names>D. R.</given-names>
<surname>Martinez</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Tsybovsky</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Phung</surname></string-name>, <string-name><given-names>O. M.</given-names>
<surname>Abiona</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Antia</surname></string-name>, <string-name><given-names>E. M.</given-names>
<surname>Cale</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>Chang</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Choe</surname></string-name>, <string-name><given-names>K. S.</given-names>
<surname>Corbett</surname></string-name>, <string-name><given-names>R. L.</given-names>
<surname>Davis</surname></string-name>, <string-name><given-names>A. T.</given-names>
<surname>DiPiazza</surname></string-name>, <string-name><given-names>I. J.</given-names>
<surname>Gordon</surname></string-name>, <string-name><given-names>S. H.</given-names>
<surname>Hait</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Hermanus</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Kgagudi</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Laboune</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Leung</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>R. D.</given-names>
<surname>Mason</surname></string-name>, <string-name><given-names>A. F.</given-names>
<surname>Nazzari</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Novik</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>O&#x02019;Connell</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>O&#x02019;Dell</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Olia</surname></string-name>, <string-name><given-names>S. D.</given-names>
<surname>Schmidt</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Stephens</surname></string-name>, <string-name><given-names>C. D.</given-names>
<surname>Stringham</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Talana</surname></string-name>, <string-name><given-names>I.-T.</given-names>
<surname>Teng</surname></string-name>, <string-name><given-names>D. A.</given-names>
<surname>Wagner</surname></string-name>, <string-name><given-names>A. T.</given-names>
<surname>Widge</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Roederer</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Ledgerwood</surname></string-name>, <string-name><given-names>T. J.</given-names>
<surname>Ruckwardt</surname></string-name>, <string-name><given-names>M. R.</given-names>
<surname>Gaudinski</surname></string-name>, <string-name><given-names>P. L.</given-names>
<surname>Moore</surname></string-name>, <string-name><given-names>N. A.</given-names>
<surname>Doria-Rose</surname></string-name>, <string-name><given-names>R. S.</given-names>
<surname>Baric</surname></string-name>, <string-name><given-names>B. S.</given-names>
<surname>Graham</surname></string-name>, <string-name><given-names>A. B.</given-names>
<surname>McDermott</surname></string-name>, <string-name><given-names>D. C.</given-names>
<surname>Douek</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Kwong</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Mascola</surname></string-name>, <string-name><given-names>N. J.</given-names>
<surname>Sullivan</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Misasi</surname></string-name></person-group>, 
<article-title>Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants</article-title>. <source>Science</source>
<volume>373</volume>, 
<fpage>eabh1766</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34210892</pub-id>
</mixed-citation></ref><ref id="R74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. L.</given-names>
<surname>Berkowitz</surname></string-name>, <string-name><given-names>D. A.</given-names>
<surname>Ostrov</surname></string-name></person-group>, 
<article-title>The elusive coreceptors for the SARS-CoV-2 spike protein</article-title>. <source>Viruses</source>
<volume>15</volume>, 
<fpage>67</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">36680105</pub-id>
</mixed-citation></ref><ref id="R75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Xiong</surname></string-name>, <string-name><given-names>Y.-J.</given-names>
<surname>Park</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Snijder</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Quispe</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Cameroni</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Gopal</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Dai</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lanzavecchia</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Zambon</surname></string-name>, <string-name><given-names>F. A.</given-names>
<surname>Rey</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Unexpected receptor functional mimicry elucidates activation of coronavirus fusion</article-title>. <source>Cell</source>
<volume>176</volume>, 
<fpage>1026</fpage>&#x02013;<lpage>1039.e15</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30712865</pub-id>
</mixed-citation></ref><ref id="R76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. E.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>J. B.</given-names>
<surname>Case</surname></string-name>, <string-name><given-names>E. S.</given-names>
<surname>Winkler</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>VanBlargan</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Errico</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Xie</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Suryadevara</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Gilchuk</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Zost</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Tahan</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Droit</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Turner</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>A. J.</given-names>
<surname>Schmitz</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Thapa</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>A. C. M.</given-names>
<surname>Boon</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Presti</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>O&#x02019;Halloran</surname></string-name>, <string-name><given-names>A. H. J.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Deepak</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pinto</surname></string-name>, <string-name><given-names>D. H.</given-names>
<surname>Fremont</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Crowe</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Virgin</surname></string-name>, <string-name><given-names>A. H.</given-names>
<surname>Ellebedy</surname></string-name>, <string-name><given-names>P.-Y.</given-names>
<surname>Shi</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Diamond</surname></string-name></person-group>, 
<article-title>Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies</article-title>. <source>Nat. Med.</source>
<volume>27</volume>, 
<fpage>717</fpage>&#x02013;<lpage>726</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33664494</pub-id>
</mixed-citation></ref><ref id="R77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Planas</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veyer</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Baidaliuk</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Staropoli</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Guivel-Benhassine</surname></string-name>, <string-name><given-names>M. M.</given-names>
<surname>Rajah</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Planchais</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Porrot</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Robillard</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Puech</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Prot</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Gallais</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Gantner</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Velay</surname></string-name>, <string-name><given-names>J. L.</given-names>
<surname>Guen</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Kassis-Chikhani</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Edriss</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Belec</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Seve</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Courtellemont</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>P&#x000e9;r&#x000e9;</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Hocqueloux</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Fafi-Kremer</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Prazuck</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Mouquet</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Bruel</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Simon-Lori&#x000e8;re</surname></string-name>, <string-name><given-names>F. A.</given-names>
<surname>Rey</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Schwartz</surname></string-name></person-group>, 
<article-title>Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization</article-title>. <source>Nature</source>
<volume>596</volume>, 
<fpage>276</fpage>&#x02013;<lpage>280</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34237773</pub-id>
</mixed-citation></ref><ref id="R78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>V.</given-names>
<surname>Dussupt</surname></string-name>, <string-name><given-names>R. S.</given-names>
<surname>Sankhala</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Mendez-Rivera</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Townsley</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Schmidt</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Wieczorek</surname></string-name>, <string-name><given-names>K. G.</given-names>
<surname>Lal</surname></string-name>, <string-name><given-names>G. C.</given-names>
<surname>Donofrio</surname></string-name>, <string-name><given-names>U.</given-names>
<surname>Tran</surname></string-name>, <string-name><given-names>N. D.</given-names>
<surname>Jackson</surname></string-name>, <string-name><given-names>W. I.</given-names>
<surname>Zaky</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Zemil</surname></string-name>, <string-name><given-names>S. R.</given-names>
<surname>Tritsch</surname></string-name>, <string-name><given-names>W.-H.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>E. J.</given-names>
<surname>Martinez</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Ahmed</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Choe</surname></string-name>, <string-name><given-names>W. C.</given-names>
<surname>Chang</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Hajduczki</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Jian</surname></string-name>, <string-name><given-names>C. E.</given-names>
<surname>Peterson</surname></string-name>, <string-name><given-names>P. A.</given-names>
<surname>Rees</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Rutkowska</surname></string-name>, <string-name><given-names>B. M.</given-names>
<surname>Slike</surname></string-name>, <string-name><given-names>C. N.</given-names>
<surname>Selverian</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Swafford</surname></string-name>, <string-name><given-names>I.-T.</given-names>
<surname>Teng</surname></string-name>, <string-name><given-names>P. V.</given-names>
<surname>Thomas</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>C. J.</given-names>
<surname>Smith</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Currier</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Kwong</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Rolland</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Davidson</surname></string-name>, <string-name><given-names>B. J.</given-names>
<surname>Doranz</surname></string-name>, <string-name><given-names>C. N.</given-names>
<surname>Mores</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Hatziioannou</surname></string-name>, <string-name><given-names>W. W.</given-names>
<surname>Reiley</surname></string-name>, <string-name><given-names>P. D.</given-names>
<surname>Bieniasz</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Paquin-Proulx</surname></string-name>, <string-name><given-names>G. D.</given-names>
<surname>Gromowski</surname></string-name>, <string-name><given-names>V. R.</given-names>
<surname>Polonis</surname></string-name>, <string-name><given-names>N. L.</given-names>
<surname>Michael</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Modjarrad</surname></string-name>, <string-name><given-names>M. G.</given-names>
<surname>Joyce</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Krebs</surname></string-name></person-group>, 
<article-title>Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations</article-title>. <source>Nat. Immunol.</source>
<volume>22</volume>, 
<fpage>1503</fpage>&#x02013;<lpage>1514</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34716452</pub-id>
</mixed-citation></ref><ref id="R79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names>
<surname>Cameroni</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Bowen</surname></string-name>, <string-name><given-names>L. E.</given-names>
<surname>Rosen</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Saliba</surname></string-name>, <string-name><given-names>S. K.</given-names>
<surname>Zepeda</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Culap</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pinto</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>VanBlargan</surname></string-name>, <string-name><given-names>A. D.</given-names>
<surname>Marco</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>di Iulio</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Zatta</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Kaiser</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Noack</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Farhat</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Czudnochowski</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Havenar-Daughton</surname></string-name>, <string-name><given-names>K. R.</given-names>
<surname>Sprouse</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Dillen</surname></string-name>, <string-name><given-names>A. E.</given-names>
<surname>Powell</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Maher</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Yin</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Sun</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Soriaga</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Bassi</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Silacci-Fregni</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Gustafsson</surname></string-name>, <string-name><given-names>N. M.</given-names>
<surname>Franko</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Logue</surname></string-name>, <string-name><given-names>N. T.</given-names>
<surname>Iqbal</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Mazzitelli</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Geffner</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Grifantini</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Chu</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Gori</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Riva</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Giannini</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Ceschi</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Ferrari</surname></string-name>, <string-name><given-names>P. E.</given-names>
<surname>Cipp&#x000e0;</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Franzetti-Pellanda</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Garzoni</surname></string-name>, <string-name><given-names>P. J.</given-names>
<surname>Halfmann</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Kawaoka</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Hebner</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>Purcell</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Piccoli</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Pizzuto</surname></string-name>, <string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Diamond</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Telenti</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Virgin</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lanzavecchia</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Snell</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name></person-group>, 
<article-title>Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift</article-title>. <source>Nature</source>
<volume>602</volume>, 
<fpage>664</fpage>&#x02013;<lpage>670</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35016195</pub-id>
</mixed-citation></ref><ref id="R80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Iketani</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Guo</surname></string-name>, <string-name><given-names>J. F.-W.</given-names>
<surname>Chan</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Luo</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Chu</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Nair</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>K. K.-H.</given-names>
<surname>Chik</surname></string-name>, <string-name><given-names>T. T.-T.</given-names>
<surname>Yuen</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Yoon</surname></string-name>, <collab id="coll02">K. K.-W. To</collab>, <string-name><given-names>H.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>M. T.</given-names>
<surname>Yin</surname></string-name>, <string-name><given-names>M. E.</given-names>
<surname>Sobieszczyk</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>H. H.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Sheng</surname></string-name>, <string-name><given-names>K.-Y.</given-names>
<surname>Yuen</surname></string-name>, <string-name><given-names>D. D.</given-names>
<surname>Ho</surname></string-name></person-group>, 
<article-title>Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2</article-title>. <source>Nature</source>
<volume>602</volume>, 
<fpage>676</fpage>&#x02013;<lpage>681</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35016198</pub-id>
</mixed-citation></ref><ref id="R81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Mannar</surname></string-name>, <string-name><given-names>J. W.</given-names>
<surname>Saville</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Zhu</surname></string-name>, <string-name><given-names>S. S.</given-names>
<surname>Srivastava</surname></string-name>, <string-name><given-names>A. M.</given-names>
<surname>Berezuk</surname></string-name>, <string-name><given-names>K. S.</given-names>
<surname>Tuttle</surname></string-name>, <string-name><given-names>A. C.</given-names>
<surname>Marquez</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Sekirov</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Subramaniam</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein&#x02013;ACE2 complex</article-title>. <source>Science</source>
<volume>375</volume>, 
<fpage>760</fpage>&#x02013;<lpage>764</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35050643</pub-id>
</mixed-citation></ref><ref id="R82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>McCallum</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Czudnochowski</surname></string-name>, <string-name><given-names>L. E.</given-names>
<surname>Rosen</surname></string-name>, <string-name><given-names>S. K.</given-names>
<surname>Zepeda</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Bowen</surname></string-name>, <string-name><given-names>A. C.</given-names>
<surname>Walls</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Hauser</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Joshi</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Stewart</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Dillen</surname></string-name>, <string-name><given-names>A. E.</given-names>
<surname>Powell</surname></string-name>, <string-name><given-names>T. I.</given-names>
<surname>Croll</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Nix</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Virgin</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Corti</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Snell</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name></person-group>, 
<article-title>Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement</article-title>. <source>Science</source>
<volume>375</volume>, 
<fpage>864</fpage>&#x02013;<lpage>868</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35076256</pub-id>
</mixed-citation></ref><ref id="R83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. H.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>F. L.</given-names>
<surname>Kearns</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Rosenfeld</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Votapka</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Casalino</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Papanikolas</surname></string-name>, <string-name><given-names>R. E.</given-names>
<surname>Amaro</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Freeman</surname></string-name></person-group>, 
<article-title>SARS-CoV-2 evolved variants optimize binding to cellular glycocalyx</article-title>. <source>Cell Rep. Phys. Sci.</source>
<volume>4</volume>, 
<fpage>101346</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37077408</pub-id>
</mixed-citation></ref><ref id="R84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. H. D.</given-names>
<surname>Crawford</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Eguia</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Dingens</surname></string-name>, <string-name><given-names>A. N.</given-names>
<surname>Loes</surname></string-name>, <string-name><given-names>K. D.</given-names>
<surname>Malone</surname></string-name>, <string-name><given-names>C. R.</given-names>
<surname>Wolf</surname></string-name>, <string-name><given-names>H. Y.</given-names>
<surname>Chu</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tortorici</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Veesler</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Murphy</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Pettie</surname></string-name>, <string-name><given-names>N. P.</given-names>
<surname>King</surname></string-name>, <string-name><given-names>A. B.</given-names>
<surname>Balazs</surname></string-name>, <string-name><given-names>J. D.</given-names>
<surname>Bloom</surname></string-name></person-group>, 
<article-title>Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays</article-title>. <source>Viruses</source>
<volume>12</volume>, 
<fpage>513</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32384820</pub-id>
</mixed-citation></ref><ref id="R85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P. D.</given-names>
<surname>Kwong</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Wyatt</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Robinson</surname></string-name>, <string-name><given-names>R. W.</given-names>
<surname>Sweet</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Sodroski</surname></string-name>, <string-name><given-names>W. A.</given-names>
<surname>Hendrickson</surname></string-name></person-group>, 
<article-title>Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody</article-title>. <source>Nature</source>
<volume>393</volume>, 
<fpage>648</fpage>&#x02013;<lpage>659</lpage> (<year>1998</year>).<pub-id pub-id-type="pmid">9641677</pub-id>
</mixed-citation></ref><ref id="R86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. I.</given-names>
<surname>Connor</surname></string-name>, <string-name><given-names>B. K.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Choe</surname></string-name>, <string-name><given-names>N. R.</given-names>
<surname>Landau</surname></string-name></person-group>, 
<article-title>Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes</article-title>. <source>Virology</source>
<volume>206</volume>, 
<fpage>935</fpage>&#x02013;<lpage>944</lpage> (<year>1995</year>).<pub-id pub-id-type="pmid">7531918</pub-id>
</mixed-citation></ref><ref id="R87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Jain</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Govindan</surname></string-name>, <string-name><given-names>A. R.</given-names>
<surname>Berkman</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Luban</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>D&#x000ed;az-Salinas</surname></string-name>, <string-name><given-names>N. D.</given-names>
<surname>Durham</surname></string-name>, <string-name><given-names>J. B.</given-names>
<surname>Munro</surname></string-name></person-group>, 
<article-title>Regulation of Ebola GP conformation and membrane binding by the chemical environment of the late endosome</article-title>. <source>PLOS Pathog.</source>
<volume>19</volume>, 
<fpage>e1011848</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">38055723</pub-id>
</mixed-citation></ref><ref id="R88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. K.</given-names>
<surname>Das</surname></string-name>, <string-name><given-names>U.</given-names>
<surname>Bulow</surname></string-name>, <string-name><given-names>W. E.</given-names>
<surname>Diehl</surname></string-name>, <string-name><given-names>N. D.</given-names>
<surname>Durham</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Senjobe</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Chandran</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Luban</surname></string-name>, <string-name><given-names>J. B.</given-names>
<surname>Munro</surname></string-name></person-group>, 
<article-title>Conformational changes in the Ebola virus membrane fusion machine induced by pH, Ca<sup>2+</sup>, and receptor binding</article-title>. <source>PLoS Biol.</source>
<volume>18</volume>, 
<fpage>e3000626</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32040508</pub-id>
</mixed-citation></ref><ref id="R89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>H&#x000fc;bner</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Spinelli</surname></string-name>, <string-name><given-names>B. K.</given-names>
<surname>Chen</surname></string-name></person-group>, 
<article-title>Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained env-dependent neutralization-resistant virological synapses</article-title>. <source>J. Virol.</source>
<volume>81</volume>, 
<fpage>12582</fpage>&#x02013;<lpage>12595</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17728240</pub-id>
</mixed-citation></ref><ref id="R90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Votteler</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Ogohara</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Yi</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Hsia</surname></string-name>, <string-name><given-names>U.</given-names>
<surname>Nattermann</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Belnap</surname></string-name>, <string-name><given-names>N. P.</given-names>
<surname>King</surname></string-name>, <string-name><given-names>W. I.</given-names>
<surname>Sundquist</surname></string-name></person-group>, 
<article-title>Designed proteins induce the formation of nanocage-containing extracellular vesicles</article-title>. <source>Nature</source>
<volume>540</volume>, 
<fpage>292</fpage>&#x02013;<lpage>295</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27919066</pub-id>
</mixed-citation></ref><ref id="R91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Tiller</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Meffre</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Yurasov</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Tsuiji</surname></string-name>, <string-name><given-names>M. C.</given-names>
<surname>Nussenzweig</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Wardemann</surname></string-name></person-group>, 
<article-title>Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning</article-title>. <source>J. Immunol. Methods</source>
<volume>329</volume>, 
<fpage>112</fpage>&#x02013;<lpage>124</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">17996249</pub-id>
</mixed-citation></ref><ref id="R92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Matsuyama</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Nao</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Shirato</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Kawase</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Saito</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Takayama</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Nagata</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Sekizuka</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Katoh</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Kato</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Sakata</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Tahara</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kutsuna</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Ohmagari</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Kuroda</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Suzuki</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Kageyama</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Takeda</surname></string-name></person-group>, 
<article-title>Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>117</volume>, 
<fpage>7001</fpage>&#x02013;<lpage>7003</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32165541</pub-id>
</mixed-citation></ref><ref id="R93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Koch</surname></string-name>, <string-name><given-names>Z. M.</given-names>
<surname>Uckeley</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Doldan</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Stanifer</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Boulant</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Lozach</surname></string-name></person-group>, 
<article-title>TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells</article-title>. <source>EMBO J.</source>
<volume>40</volume>, 
<fpage>e107821</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34159616</pub-id>
</mixed-citation></ref><ref id="R94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>Feng</surname></string-name>, <string-name><given-names>N. M.</given-names>
<surname>Stamatos</surname></string-name>, <string-name><given-names>A. I.</given-names>
<surname>Dragan</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Medvedev</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Whitford</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Song</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Rallabhandi</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Cole</surname></string-name>, <string-name><given-names>Q. M.</given-names>
<surname>Nhu</surname></string-name>, <string-name><given-names>S. N.</given-names>
<surname>Vogel</surname></string-name>, <string-name><given-names>C. D.</given-names>
<surname>Geddes</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Cross</surname></string-name></person-group>, 
<article-title>Sialyl residues modulate LPS-mediated signaling through the toll-like receptor 4 complex</article-title>. <source>PLOS ONE</source>
<volume>7</volume>, 
<fpage>e32359</fpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22496731</pub-id>
</mixed-citation></ref><ref id="R95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>S&#x000e1;nchez-Felipe</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Villar</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Mu&#x000f1;oz-Barroso</surname></string-name></person-group>, 
<article-title>&#x003b1;2-3- and &#x003b1;2-6- N-linked sialic acids allow efficient interaction of newcastle disease virus with target cells</article-title>. <source>Glycoconj. J.</source>
<volume>29</volume>, 
<fpage>539</fpage>&#x02013;<lpage>549</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22869099</pub-id>
</mixed-citation></ref><ref id="R96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Strobelt</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Adler</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Shaul</surname></string-name></person-group>, 
<article-title>The transmembrane protease serine 2 (TMPRSS2) non-protease domains regulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-mediated virus entry</article-title>. <source>Viruses</source>
<volume>15</volume>, 
<fpage>2124</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37896901</pub-id>
</mixed-citation></ref><ref id="R97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>V. C.</given-names>
<surname>Ducas</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Rhoades</surname></string-name></person-group>, 
<article-title>Quantifying interactions of &#x003b2;-synuclein and &#x003b3;-synuclein with model membranes</article-title>. <source>J. Mol. Biol.</source>
<volume>423</volume>, 
<fpage>528</fpage>&#x02013;<lpage>539</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22922472</pub-id>
</mixed-citation></ref><ref id="R98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Ries</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Schwille</surname></string-name></person-group>, 
<article-title>Fluorescence correlation spectroscopy</article-title>. <source>Bioessays</source>
<volume>34</volume>, 
<fpage>361</fpage>&#x02013;<lpage>368</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22415816</pub-id>
</mixed-citation></ref><ref id="R99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N. D.</given-names>
<surname>Durham</surname></string-name>, <string-name><given-names>A. R.</given-names>
<surname>Howard</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Govindan</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Senjobe</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Fels</surname></string-name>, <string-name><given-names>W. E.</given-names>
<surname>Diehl</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Luban</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Chandran</surname></string-name>, <string-name><given-names>J. B.</given-names>
<surname>Munro</surname></string-name></person-group>, 
<article-title>Real-time analysis of individual ebola virus glycoproteins reveals pre-fusion, entry-relevant conformational dynamics</article-title>. <source>Viruses</source>
<volume>12</volume>, 
<fpage>103</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">31952255</pub-id>
</mixed-citation></ref><ref id="R100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. J.</given-names>
<surname>Blakemore</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Burnett</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Swanson</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kharytonchyk</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Telesnitsky</surname></string-name>, <string-name><given-names>J. B.</given-names>
<surname>Munro</surname></string-name></person-group>, 
<article-title>Stability and conformation of the dimeric HIV-1 genomic RNA 5&#x02032;UTR</article-title>. <source>Biophys. J.</source>
<volume>120</volume>, 
<fpage>4874</fpage>&#x02013;<lpage>4890</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34529947</pub-id>
</mixed-citation></ref><ref id="R101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. D.</given-names>
<surname>Edelstein</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Tsuchida</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Amodaj</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Pinkard</surname></string-name>, <string-name><given-names>R. D.</given-names>
<surname>Vale</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Stuurman</surname></string-name></person-group>, 
<article-title>Advanced methods of microscope control using &#x003bc;Manager software</article-title>. <source>J. Biol. Methods</source>
<volume>1</volume>, 
<fpage>e10</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25606571</pub-id>
</mixed-citation></ref><ref id="R102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. F.</given-names>
<surname>Juette</surname></string-name>, <string-name><given-names>D. S.</given-names>
<surname>Terry</surname></string-name>, <string-name><given-names>M. R.</given-names>
<surname>Wasserman</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Altman</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Zhao</surname></string-name>, <string-name><given-names>S. C.</given-names>
<surname>Blanchard</surname></string-name></person-group>, 
<article-title>Single-molecule imaging of non-equilibrium molecular ensembles on the millisecond timescale</article-title>. <source>Nat. Methods</source>
<volume>13</volume>, 
<fpage>341</fpage>&#x02013;<lpage>344</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">26878382</pub-id>
</mixed-citation></ref><ref id="R103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>F.</given-names>
<surname>Qin</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Auerbach</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Sachs</surname></string-name></person-group>, 
<article-title>A direct optimization approach to hidden markov modeling for single channel kinetics</article-title>. <source>Biophys. J.</source>
<volume>79</volume>, 
<fpage>1915</fpage>&#x02013;<lpage>1927</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">11023897</pub-id>
</mixed-citation></ref></ref-list></back></article>